KR20220106232A - 키랄 디자인 - Google Patents
키랄 디자인 Download PDFInfo
- Publication number
- KR20220106232A KR20220106232A KR1020227024673A KR20227024673A KR20220106232A KR 20220106232 A KR20220106232 A KR 20220106232A KR 1020227024673 A KR1020227024673 A KR 1020227024673A KR 20227024673 A KR20227024673 A KR 20227024673A KR 20220106232 A KR20220106232 A KR 20220106232A
- Authority
- KR
- South Korea
- Prior art keywords
- oligonucleotide
- composition
- oligonucleotides
- sequence
- chirally controlled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Window Of Vehicle (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Liquid Crystal Substances (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020237036550A KR20230152178A (ko) | 2014-01-16 | 2015-01-16 | 키랄 디자인 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461928405P | 2014-01-16 | 2014-01-16 | |
| US61/928,405 | 2014-01-16 | ||
| US201462063359P | 2014-10-13 | 2014-10-13 | |
| US62/063,359 | 2014-10-13 | ||
| PCT/IB2015/000395 WO2015107425A2 (en) | 2014-01-16 | 2015-01-16 | Chiral design |
| KR1020167022289A KR102423317B1 (ko) | 2014-01-16 | 2015-01-16 | 키랄 디자인 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167022289A Division KR102423317B1 (ko) | 2014-01-16 | 2015-01-16 | 키랄 디자인 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237036550A Division KR20230152178A (ko) | 2014-01-16 | 2015-01-16 | 키랄 디자인 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220106232A true KR20220106232A (ko) | 2022-07-28 |
Family
ID=53039535
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227024673A Abandoned KR20220106232A (ko) | 2014-01-16 | 2015-01-16 | 키랄 디자인 |
| KR1020167022289A Active KR102423317B1 (ko) | 2014-01-16 | 2015-01-16 | 키랄 디자인 |
| KR1020247037406A Ceased KR20240164968A (ko) | 2014-01-16 | 2015-01-16 | 키랄 디자인 |
| KR1020257039389A Pending KR20250172722A (ko) | 2014-01-16 | 2015-01-16 | 키랄 디자인 |
| KR1020237036550A Ceased KR20230152178A (ko) | 2014-01-16 | 2015-01-16 | 키랄 디자인 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167022289A Active KR102423317B1 (ko) | 2014-01-16 | 2015-01-16 | 키랄 디자인 |
| KR1020247037406A Ceased KR20240164968A (ko) | 2014-01-16 | 2015-01-16 | 키랄 디자인 |
| KR1020257039389A Pending KR20250172722A (ko) | 2014-01-16 | 2015-01-16 | 키랄 디자인 |
| KR1020237036550A Ceased KR20230152178A (ko) | 2014-01-16 | 2015-01-16 | 키랄 디자인 |
Country Status (19)
Families Citing this family (144)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0923225A2 (pt) | 2008-12-02 | 2016-10-04 | Chiralgen Ltd | metodo para sintese de acidos nucleicos modificados no atomo de fosforo |
| EP2451461A4 (en) | 2009-07-06 | 2013-05-29 | Ontorii Inc | NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF |
| DK2620428T3 (da) | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
| CN107365339A (zh) | 2011-07-19 | 2017-11-21 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| SG11201500243WA (en) | 2012-07-13 | 2015-04-29 | Shin Nippon Biomedical Lab Ltd | Chiral nucleic acid adjuvant |
| DK2872147T3 (da) | 2012-07-13 | 2023-02-20 | Wave Life Sciences Ltd | Fremgangsmåde til fremstilling af kirale oligonukleotider |
| WO2014010250A1 (en) | 2012-07-13 | 2014-01-16 | Chiralgen, Ltd. | Asymmetric auxiliary group |
| EP3095459A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
| EP3095461A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| WO2015108046A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
| EP3094728B1 (en) | 2014-01-16 | 2022-03-09 | Wave Life Sciences Ltd. | Chiral design |
| RU2708237C2 (ru) | 2014-08-22 | 2019-12-05 | Общество с ограниченной ответственностью "НооГен" | Модифицированные олигонуклеотиды и способ их получения |
| DK3234131T3 (da) | 2014-12-16 | 2020-06-29 | Roche Innovation Ct Copenhagen As | Fremgangsmåde til screening af kiral toksicitet |
| AU2015367378A1 (en) | 2014-12-17 | 2017-06-15 | Proqr Therapeutics Ii B.V. | Targeted RNA editing |
| CN117965536A (zh) | 2015-07-22 | 2024-05-03 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| MA46427A (fr) * | 2015-10-09 | 2018-08-15 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| CA3119019C (en) | 2015-12-10 | 2024-06-11 | Ptc Therapeutics, Inc. | Compounds and methods for treating huntington's disease |
| MA43822A (fr) | 2016-03-13 | 2018-11-28 | Wave Life Sciences Ltd | Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides |
| MA45471A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques de phosphatidylinositol-3-kinase et leurs utilisations |
| WO2017173297A1 (en) | 2016-04-01 | 2017-10-05 | Avidity Biosciences Llc | Beta-catenin nucleic acids and uses thereof |
| US10876121B2 (en) | 2016-04-01 | 2020-12-29 | Avidity Biosciences, Inc. | EGFR nucleic acids and uses thereof |
| KR102775461B1 (ko) | 2016-04-01 | 2025-02-28 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩타이드 조성물 및 이의 용도 |
| US10858656B2 (en) | 2016-04-01 | 2020-12-08 | Avidity Biosciences, Inc. | KRAS nucleic acids and uses thereof |
| US11060089B2 (en) | 2016-04-18 | 2021-07-13 | Sarepta Therapeutics, Inc. | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
| JP7042255B2 (ja) | 2016-04-29 | 2022-03-25 | サレプタ セラピューティクス, インコーポレイテッド | ヒトlmnaを標的にするオリゴヌクレオチド類縁体 |
| EP3452596A4 (en) * | 2016-05-04 | 2020-03-18 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS |
| JP2019516679A (ja) * | 2016-05-04 | 2019-06-20 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | 生物活性剤に関する方法および組成物 |
| US11013757B2 (en) | 2016-06-03 | 2021-05-25 | Wave Life Sciences Ltd. | Oligonucleotides, compositions and methods thereof |
| EP3475424A1 (en) | 2016-06-22 | 2019-05-01 | ProQR Therapeutics II B.V. | Single-stranded rna-editing oligonucleotides |
| KR20190024977A (ko) | 2016-06-30 | 2019-03-08 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이상증에 대한 엑손 스킵핑 올리고머 |
| WO2018041973A1 (en) | 2016-09-01 | 2018-03-08 | Proqr Therapeutics Ii B.V. | Chemically modified single-stranded rna-editing oligonucleotides |
| WO2018098264A1 (en) | 2016-11-23 | 2018-05-31 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| US20180193270A1 (en) | 2016-11-29 | 2018-07-12 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| NZ755416A (en) | 2016-12-19 | 2023-05-26 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
| ES3051834T3 (en) | 2016-12-19 | 2025-12-30 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
| PT4122497T (pt) | 2016-12-19 | 2024-06-12 | Sarepta Therapeutics Inc | Conjugados oligoméricos de salto de exão para a distrofia muscular |
| KR20240172236A (ko) | 2017-01-06 | 2024-12-09 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법 |
| WO2018150196A1 (en) | 2017-02-17 | 2018-08-23 | Oxford University Innovation Limited | Cell penetrating peptides modified by glycosylation |
| BR112019021520A2 (pt) | 2017-04-14 | 2020-08-04 | Tollnine, Inc. | oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune |
| CA3065523A1 (en) | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| US11603532B2 (en) | 2017-06-02 | 2023-03-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| CN111164091B (zh) * | 2017-06-02 | 2025-01-07 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
| EP4151627A1 (en) | 2017-06-05 | 2023-03-22 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| WO2018237194A1 (en) | 2017-06-21 | 2018-12-27 | Wave Life Sciences Ltd. | Compounds, compositions and methods for synthesis |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| CN111163838B (zh) | 2017-06-28 | 2023-03-28 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| AU2018316159A1 (en) | 2017-08-08 | 2020-02-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| CN111108096A (zh) | 2017-09-18 | 2020-05-05 | 波涛生命科学有限公司 | 寡核苷酸制备技术 |
| SG11202002517RA (en) | 2017-09-22 | 2020-04-29 | Avidity Biosciences Inc | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
| EA201991450A1 (ru) | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
| JP2020536060A (ja) | 2017-09-28 | 2020-12-10 | サレプタ セラピューティクス, インコーポレイテッド | 筋ジストロフィーを処置するための併用療法 |
| JP2020536058A (ja) | 2017-09-28 | 2020-12-10 | サレプタ セラピューティクス, インコーポレイテッド | 筋ジストロフィーを処置するための併用療法 |
| EP3687519A1 (en) | 2017-09-28 | 2020-08-05 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
| SG11202003126VA (en) | 2017-10-04 | 2020-05-28 | Avidity Biosciences Inc | Nucleic acid-polypeptide compositions and uses thereof |
| EP3694530A4 (en) * | 2017-10-12 | 2021-06-30 | Wave Life Sciences Ltd. | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
| CN111226114A (zh) | 2017-10-13 | 2020-06-02 | 罗氏创新中心哥本哈根有限公司 | 用部分立体限定的寡核苷酸子文库鉴定反义寡核苷酸改进的立体限定硫代磷酸酯寡核苷酸变体的方法 |
| US11555189B2 (en) | 2017-10-18 | 2023-01-17 | Sarepta Therapeutics, Inc. | Antisense oligomer compounds |
| PL3717646T3 (pl) | 2017-12-01 | 2025-10-27 | The Texas A&M University System | Leczenie antysensowe zespołu angelmana |
| CN118638787A (zh) | 2017-12-06 | 2024-09-13 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| JP7348185B2 (ja) * | 2017-12-21 | 2023-09-20 | アルニラム ファーマスーティカルズ インコーポレイテッド | キラル富化二本鎖rna剤 |
| CA3088522A1 (en) * | 2018-01-15 | 2019-07-18 | Ionis Pharmaceuticals, Inc. | Modulators of dnm2 expression |
| BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| JP2021521140A (ja) * | 2018-04-12 | 2021-08-26 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | オリゴヌクレオチド組成物及びその使用方法 |
| CA3098623A1 (en) | 2018-05-07 | 2019-11-14 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
| CA3098624A1 (en) | 2018-05-11 | 2019-11-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| US10765760B2 (en) | 2018-05-29 | 2020-09-08 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| EP4219717A3 (en) | 2018-06-13 | 2023-12-20 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystrophy |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| KR20210038845A (ko) | 2018-06-27 | 2021-04-08 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료를 위한 헤테로아릴 화합물 |
| TW202449155A (zh) | 2018-07-27 | 2024-12-16 | 美商薩羅塔治療公司 | 用於肌肉萎縮症之外顯子跳躍寡聚物 |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| GB201812980D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| GB201812972D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| AU2019392928A1 (en) * | 2018-12-06 | 2021-06-17 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| AU2019394177A1 (en) | 2018-12-07 | 2021-06-10 | Oxford University Innovation Limited | Linkers |
| BR112021011018A2 (pt) | 2018-12-13 | 2021-08-31 | Sarepta Therapeutics, Inc. | Conjugados de oligômero para exon skipping para distrofia muscular |
| JP2022515744A (ja) | 2018-12-20 | 2022-02-22 | プラクシス プレシジョン メディシンズ, インコーポレイテッド | Kcnt1関連障害の治療のための組成物及び方法 |
| IL312067B2 (en) | 2018-12-21 | 2025-08-01 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and uses thereof |
| AU2020241559A1 (en) | 2019-03-20 | 2021-11-11 | Wave Life Sciences Ltd. | Technologies useful for oligonucleotide preparation |
| JPWO2020196662A1 (cg-RX-API-DMAC7.html) * | 2019-03-25 | 2020-10-01 | ||
| WO2020214763A1 (en) | 2019-04-18 | 2020-10-22 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
| WO2020219820A1 (en) | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| EP3958872A4 (en) * | 2019-04-25 | 2024-07-03 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| MX2021012981A (es) * | 2019-04-25 | 2022-01-18 | Wave Life Sciences Ltd | Composiciones de oligonucleotido y metodos de uso de las mismas. |
| CA3139821A1 (en) | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| WO2020247782A1 (en) | 2019-06-06 | 2020-12-10 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and uses thereof |
| JP7581252B2 (ja) | 2019-06-06 | 2024-11-12 | アビディティー バイオサイエンシーズ,インク. | Unaアミダイトおよびその使用 |
| CA3154768A1 (en) * | 2019-10-06 | 2021-04-15 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| US20240148891A1 (en) | 2019-10-18 | 2024-05-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| TW202131920A (zh) | 2019-11-01 | 2021-09-01 | 瑞士商諾華公司 | 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途 |
| JP7858532B2 (ja) | 2020-01-10 | 2026-05-14 | ダイン セラピューティクス,インコーポレーテッド | 筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用 |
| TW202144572A (zh) | 2020-03-19 | 2021-12-01 | 美商亞維代堤生物科學公司 | 治療臉肩胛肱骨肌肉失養症之組合物及方法 |
| KR102927945B1 (ko) | 2020-03-27 | 2026-02-23 | 어비디티 바이오사이언시스 인크. | 근이영양증의 치료용 조성물 및 방법 |
| MX2022014606A (es) * | 2020-05-22 | 2023-03-08 | Wave Life Sciences Ltd | Composiciones de oligonucleótidos bicatenarios y métodos relacionados con las mismas. |
| KR20230117182A (ko) | 2020-12-04 | 2023-08-07 | 다인 세라퓨틱스, 인크. | 항체-올리고뉴클레오티드 복합체 및 그의 용도 |
| AU2021414227A1 (en) | 2020-12-31 | 2023-07-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| CA3211038A1 (en) | 2021-02-12 | 2022-08-18 | Oxford University Innovation Limited | Cell-penetrating peptide conjugates and methods of their use |
| WO2022194924A1 (en) | 2021-03-18 | 2022-09-22 | Boehringer Ingelheim International Gmbh | Chiral synthons for the synthesis of chiral phosphorothioates |
| TW202304446A (zh) | 2021-03-29 | 2023-02-01 | 瑞士商諾華公司 | 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途 |
| KR20240159455A (ko) | 2021-06-02 | 2024-11-05 | 리제너론 파마슈티칼스 인코포레이티드 | 신경성 유전자좌 노치 상동체 단백질 3(notch3) 제제를 이용한 뇌혈관 질환의 치료 |
| EP4401792A4 (en) | 2021-09-16 | 2025-12-03 | Avidity Biosciences Inc | COMPOSITIONS AND METHODS OF TREATMENT OF FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY |
| US20240425864A1 (en) | 2021-09-30 | 2024-12-26 | Sarepta Therapeutics, Inc. | Antisense oligonucleotides having one or more abasic units |
| JP2024545602A (ja) * | 2021-11-19 | 2024-12-10 | ウェイブ ライフ サイエンシズ リミテッド | Hsd17b13関連二本鎖オリゴヌクレオチド組成物及びそれに関連する方法 |
| EP4479535A1 (en) | 2022-02-14 | 2024-12-25 | ProQR Therapeutics II B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
| EP4555085A1 (en) | 2022-07-15 | 2025-05-21 | ProQR Therapeutics II B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
| EP4555086A1 (en) | 2022-07-15 | 2025-05-21 | ProQR Therapeutics II B.V. | Oligonucleotides for adar-mediated rna editing and use thereof |
| CN120659627A (zh) | 2022-07-29 | 2025-09-16 | 瑞泽恩制药公司 | 用于转铁蛋白受体(tfr)介导的脑和肌肉递送的组合物和方法 |
| EP4590311A2 (en) | 2022-09-21 | 2025-07-30 | Sarepta Therapeutics, Inc. | Dmd antisense oligonucleotide-mediated exon skipping efficiency |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| AU2023371614A1 (en) | 2022-11-04 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
| AU2023379457A1 (en) | 2022-11-14 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
| KR20250113455A (ko) | 2022-11-24 | 2025-07-25 | 프로큐알 테라퓨틱스 Ⅱ 비.브이. | 유전성 hfe-혈색소침착증의 치료를 위한 안티센스 올리고뉴클레오티드 |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| WO2024121373A1 (en) | 2022-12-09 | 2024-06-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of cardiovascular disease |
| GB202300865D0 (en) | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
| EP4654982A1 (en) | 2023-01-27 | 2025-12-03 | Regeneron Pharmaceuticals, Inc. | Modified rhabdovirus glycoproteins and uses thereof |
| WO2024175550A1 (en) | 2023-02-20 | 2024-08-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
| JP2026510408A (ja) | 2023-03-24 | 2026-04-02 | プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ | 神経障害の処置のためのアンチセンスオリゴヌクレオチド |
| EP4688143A1 (en) | 2023-03-27 | 2026-02-11 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of liver disease |
| EP4702144A1 (en) | 2023-04-27 | 2026-03-04 | Sarepta Therapeutics, Inc. | Antisense oligomers for treatment of chronic kidney disease |
| WO2024256620A1 (en) | 2023-06-16 | 2024-12-19 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurodegenerative disease |
| US12491257B2 (en) | 2023-06-27 | 2025-12-09 | Avidity Biosciences, Inc. | Compositions and methods of using PRKAG2-targeting antibody-oligonucleotide conjugates |
| AU2024308906A1 (en) | 2023-06-30 | 2026-02-05 | Atrium Therapeutics, Inc. | Compositions and methods of using pln-targeting antibody-oligonucleotide conjugates |
| AU2024287308A1 (en) | 2023-07-13 | 2025-12-18 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| EP4774393A1 (en) | 2023-09-07 | 2026-07-15 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2025085810A2 (en) | 2023-10-18 | 2025-04-24 | Sarepta Therapeutics, Inc. | Antisense oligomers for treatment of centronuclear myopathies |
| WO2025096809A1 (en) | 2023-10-31 | 2025-05-08 | Korro Bio, Inc. | Oligonucleotides comprising phosphoramidate internucleotide linkages |
| AU2024379264A1 (en) | 2023-11-16 | 2026-05-14 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of classic galactosemia |
| WO2025128799A1 (en) | 2023-12-12 | 2025-06-19 | Korro Bio, Inc. | Double-stranded rna-editing oligonucleotides and uses thereof |
| AU2024402199A1 (en) | 2023-12-20 | 2026-07-16 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of huntington's disease |
| GB202404661D0 (en) | 2024-04-02 | 2024-05-15 | Proqr Therapeutics Ii Bv | Antisense oligoncleotides for the treatment of liver disease |
| WO2025224230A1 (en) | 2024-04-25 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of fatty liver disease |
| WO2025264554A1 (en) | 2024-06-17 | 2025-12-26 | Pepgen Inc. | Antisense oligonucleotide conjugates targeting peripheral myelin protein 22 (pmp22) and methods of use thereof |
| GB202410081D0 (en) | 2024-07-11 | 2024-08-28 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of cardiovascular disease |
| WO2026022136A1 (en) | 2024-07-23 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2026050243A1 (en) | 2024-08-26 | 2026-03-05 | Korro Bio, Inc. | Galnac conjugated oligonucleotides for rna editing |
| WO2026060374A2 (en) | 2024-09-16 | 2026-03-19 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| WO2026068781A1 (en) | 2024-09-30 | 2026-04-02 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
| WO2026093339A1 (en) | 2024-10-29 | 2026-05-07 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of peroxisome biogenesis disorders in the zellweger spectrum (pbd-zsd) |
| WO2026122478A1 (en) | 2024-12-02 | 2026-06-11 | Korro Bio, Inc. | Extrahepatic delivery formulations and methods |
| WO2026136663A1 (en) | 2024-12-18 | 2026-06-25 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurodegenerative disease |
Family Cites Families (711)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2878264A (en) | 1959-03-17 | Substituted amino alcohols | ||
| US513030A (en) | 1894-01-16 | Machine for waxing or coating paper | ||
| DE1144279B (de) | 1957-09-26 | 1963-02-28 | Robins Co Inc A H | Verfahren zur Herstellung von 3-Aryl-3-hydroxypyrrolidinen und deren Salzen |
| US3135766A (en) | 1961-10-03 | 1964-06-02 | Mead Johnson & Co | 3-substituted-3-pyrrolidinols |
| US3484473A (en) | 1967-05-12 | 1969-12-16 | Buckman Labor Inc | Methylene bisesters of thiolsulfonic acids |
| DE1934150A1 (de) | 1968-07-10 | 1970-01-15 | Pennwalt Corp | Neue 1-Alkanoyloxy-1,2,4,5-tetrahydro-3H,3-benzazepine |
| US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| US3745162A (en) | 1970-08-31 | 1973-07-10 | Robins Co Inc A H | 1,2,3,4-tetrahydroisoquinoline-2-(thio)-carboxamides |
| GB1448437A (en) | 1973-02-24 | 1976-09-08 | Beecham Group Ltd | Diphenylpropylamines |
| US4022791A (en) | 1975-06-03 | 1977-05-10 | Pfizer Inc. | 2-Aminomethyl-3,4-dihydronaphthalenes |
| GB1504424A (en) | 1975-08-09 | 1978-03-22 | Beecham Group Ltd | Isoquinoline-derived aminoethers |
| BR7807288A (pt) | 1977-11-08 | 1979-06-12 | Genentech Inc | Processo para sintese de polinucleotidos |
| DD133885B1 (de) | 1978-01-04 | 1981-02-25 | Hans Lehmann | Mittel zur bekaempfung von phytopathogenen bakterien und pilzen |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4542142A (en) | 1982-11-22 | 1985-09-17 | Roussel Uclaf | Insecticidal cyclopropane carboxylic acid derivatives with 3-unsaturated-side chain |
| DE3329892A1 (de) | 1983-08-18 | 1985-03-07 | Köster, Hubert, Prof. Dr., 2000 Hamburg | Verfahren zur herstellung von oligonucleotiden |
| US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
| US5643889A (en) | 1984-07-11 | 1997-07-01 | Temple University-Of The Commonwealth System Of Pennsylvania | Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof |
| FR2567892B1 (fr) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
| US5367066A (en) | 1984-10-16 | 1994-11-22 | Chiron Corporation | Oligonucleotides with selectably cleavable and/or abasic sites |
| FR2575751B1 (fr) | 1985-01-08 | 1987-04-03 | Pasteur Institut | Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques |
| FR2576898B1 (fr) | 1985-02-01 | 1988-01-08 | Lafon Labor | Derives de 3-phenyl-tetrahydropyridine, procede de preparation et utilisation en therapeutique |
| US4659774A (en) | 1985-11-01 | 1987-04-21 | American Hoechst Corporation | Support for solid-phase oligonucleotide synthesis |
| US4840956A (en) | 1986-02-18 | 1989-06-20 | Warner-Lambert Company | Novel disubstituted-7-pyrrolidinoquinoline antibacterial agents |
| US4735949A (en) | 1986-02-18 | 1988-04-05 | Warner-Lambert Company | Disubstituted-7-pyrrolidinonaphthyridine antibacterial agents |
| IL83663A0 (en) | 1986-10-27 | 1988-01-31 | Robins Co Inc A H | Preparation of 3-pyrrolidinols |
| EP0366685B1 (en) | 1987-06-24 | 1994-10-19 | Howard Florey Institute Of Experimental Physiology And Medicine | Nucleoside derivatives |
| ES2045028T3 (es) | 1987-07-30 | 1994-01-16 | Univ Bar Ilan | Esteres de acidos carboxilicos biologicamente activos. |
| US4923901A (en) | 1987-09-04 | 1990-05-08 | Millipore Corporation | Membranes with bound oligonucleotides and peptides |
| US5175273A (en) | 1988-07-01 | 1992-12-29 | Genentech, Inc. | Nucleic acid intercalating agents |
| US4945158A (en) | 1988-08-12 | 1990-07-31 | American Cyanamid Company | Antidiabetic phosphonates |
| US4943629A (en) | 1988-08-12 | 1990-07-24 | American Cyanamid Company | Antidiabetic alpha-substituted phosphonates |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5141813A (en) | 1989-08-28 | 1992-08-25 | Clontech Laboratories, Inc. | Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis |
| US5134066A (en) | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
| CA2029273A1 (en) | 1989-12-04 | 1991-06-05 | Christine L. Brakel | Modified nucleotide compounds |
| US5130302A (en) | 1989-12-20 | 1992-07-14 | Boron Bilogicals, Inc. | Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same |
| CA2071897A1 (en) | 1989-12-28 | 1991-06-29 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
| US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
| US5457191A (en) | 1990-01-11 | 1995-10-10 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
| US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
| US5635488A (en) | 1991-10-15 | 1997-06-03 | Isis Pharmaceuticals, Inc. | Compounds having phosphorodithioate linkages of high chiral purity |
| US5506212A (en) | 1990-01-11 | 1996-04-09 | Isis Pharmaceuticals, Inc. | Oligonucleotides with substantially chirally pure phosphorothioate linkages |
| US5852188A (en) | 1990-01-11 | 1998-12-22 | Isis Pharmaceuticals, Inc. | Oligonucleotides having chiral phosphorus linkages |
| US5587470A (en) | 1990-01-11 | 1996-12-24 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
| US7101993B1 (en) | 1990-01-11 | 2006-09-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides containing 2′-O-modified purines |
| US5620963A (en) | 1991-10-15 | 1997-04-15 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity |
| US5212295A (en) | 1990-01-11 | 1993-05-18 | Isis Pharmaceuticals | Monomers for preparation of oligonucleotides having chiral phosphorus linkages |
| US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
| US5914396A (en) | 1990-01-11 | 1999-06-22 | Isis Pharmaceuticals, Inc. | 2'-O-modified nucleosides and phosphoramidites |
| KR927003044A (ko) | 1990-01-11 | 1992-12-17 | 크리스토퍼 케이. 미라벨리 | Rna 활성과 유전자 발현을 검출하고 조절하는 조성물 및 그 방법 |
| US6339066B1 (en) | 1990-01-11 | 2002-01-15 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C |
| US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
| US5036964A (en) | 1990-03-28 | 1991-08-06 | Dana Corporation | Armature assembly for an electromagnetic coupling |
| US5292875A (en) | 1990-04-20 | 1994-03-08 | Lynx Therapeutics, Inc. | Method of synthesizing sulfurized oligonucleotide analogs |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| ES2139578T3 (es) | 1990-05-23 | 2000-02-16 | Isis Pharmaceuticals Inc | Composiciones y procedimiento para modular la actividad del arn mediante la modificacion de la estructura protectora 5' del arn. |
| JPH0874B2 (ja) | 1990-07-27 | 1996-01-10 | アイシス・ファーマシューティカルス・インコーポレーテッド | 遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド |
| US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
| US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
| US6121433A (en) | 1990-07-27 | 2000-09-19 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having nitrogen-containing linkages |
| WO1994022886A1 (en) | 1993-03-30 | 1994-10-13 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
| US5677437A (en) | 1990-07-27 | 1997-10-14 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
| US5386023A (en) | 1990-07-27 | 1995-01-31 | Isis Pharmaceuticals | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling |
| US5783682A (en) | 1990-07-27 | 1998-07-21 | Isis Pharmaceuticals, Inc. | Oligonucleotide mimics having nitrogen-containing linkages |
| US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
| US5623070A (en) | 1990-07-27 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
| US5223618A (en) | 1990-08-13 | 1993-06-29 | Isis Pharmaceuticals, Inc. | 4'-desmethyl nucleoside analog compounds |
| US5618704A (en) | 1990-07-27 | 1997-04-08 | Isis Pharmacueticals, Inc. | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling |
| US6087482A (en) | 1990-07-27 | 2000-07-11 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
| US5688941A (en) | 1990-07-27 | 1997-11-18 | Isis Pharmaceuticals, Inc. | Methods of making conjugated 4' desmethyl nucleoside analog compounds |
| US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| US5792844A (en) | 1990-07-27 | 1998-08-11 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent nitrogen atoms |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| US5834607A (en) | 1990-07-27 | 1998-11-10 | Isis Pharmaceuticals, Inc. | Amines and methods of making and using the same |
| US5998603A (en) | 1994-09-29 | 1999-12-07 | Isis Pharmaceuticals, Inc. | 4'-desmethyl nucleoside analogs, and oligomers thereof |
| US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
| US5541307A (en) | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| US5512668A (en) | 1991-03-06 | 1996-04-30 | Polish Academy Of Sciences | Solid phase oligonucleotide synthesis using phospholane intermediates |
| US20020183502A1 (en) | 1991-05-21 | 2002-12-05 | Mesmaeker Alain De | Backbone-modified oligonucleotide analogs and methods for using same |
| US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
| US6414112B1 (en) | 1991-05-24 | 2002-07-02 | Ole Buchardt | Peptide nucleic acids having 2,6-diaminopurine nucleobases |
| BR9206131A (pt) | 1991-06-10 | 1995-05-02 | Lucky Ltd | Hepatite C: diagnóstico e vacinas |
| US5359052A (en) | 1991-08-05 | 1994-10-25 | Polish Academy Of Sciences | Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates |
| US5646267A (en) | 1991-08-05 | 1997-07-08 | Polish Academy Of Sciences | Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues |
| US6369209B1 (en) | 1999-05-03 | 2002-04-09 | Isis Pharmaceuticals, Inc. | Oligonucleotides having A-DNA form and B-DNA form conformational geometry |
| US7119184B2 (en) | 1991-08-12 | 2006-10-10 | Isis Pharmaceuticals, Inc. | Oligonucleotides having A-DNA form and B-DNA form conformational geometry |
| AU2874892A (en) | 1991-10-15 | 1993-05-21 | Isis Pharmaceuticals, Inc. | Oligonucleotides having chiral phosphorus linkages |
| US5576302A (en) | 1991-10-15 | 1996-11-19 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity |
| US5654284A (en) | 1991-10-15 | 1997-08-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity |
| US5599797A (en) | 1991-10-15 | 1997-02-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
| US5661134A (en) | 1991-10-15 | 1997-08-26 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity |
| US5607923A (en) | 1991-10-15 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity |
| DE59208572D1 (de) | 1991-10-17 | 1997-07-10 | Ciba Geigy Ag | Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte |
| US5594121A (en) | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
| US6235887B1 (en) | 1991-11-26 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines |
| US5484908A (en) | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
| US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
| ATE515510T1 (de) | 1991-12-24 | 2011-07-15 | Isis Pharmaceuticals Inc | Durch dna-abschnitte unterbrochene modifizierte oligonukleotide |
| GB9213601D0 (en) | 1992-06-26 | 1992-08-12 | Mastico Robert A | Protein based delivery system |
| US7067497B2 (en) | 1992-09-29 | 2006-06-27 | Isis Pharmaceuticals, Inc. | Modulation of telomere length by oligonucleotides having a G-core sequence |
| US6444656B1 (en) | 1992-12-23 | 2002-09-03 | Biochem Pharma, Inc. | Antiviral phosphonate nucleotides |
| US6005107A (en) | 1992-12-23 | 1999-12-21 | Biochem Pharma, Inc. | Antiviral compounds |
| DK0677056T3 (da) | 1993-01-25 | 1996-08-05 | Hybridon Inc | Oligonukleotid-alkylphosphonater og -alkylphosphonothioater |
| JPH08508489A (ja) | 1993-03-31 | 1996-09-10 | スターリング ウィンスロップ インコーポレイティド | 二官能価ヌクレオシド、それらのオリゴマーならびにそれらの製造方法及び使用方法 |
| EP0691979A1 (en) | 1993-03-31 | 1996-01-17 | Sanofi | Novel 5'-substituted nucleosides and oligomers produced therefrom |
| US5955591A (en) | 1993-05-12 | 1999-09-21 | Imbach; Jean-Louis | Phosphotriester oligonucleotides, amidites and method of preparation |
| US6015886A (en) | 1993-05-24 | 2000-01-18 | Chemgenes Corporation | Oligonucleotide phosphate esters |
| EP0628394B1 (en) | 1993-06-10 | 1998-08-26 | Idemitsu Petrochemical Co. Ltd. | Injection molding die |
| US5502177A (en) | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
| US5643989A (en) | 1993-10-29 | 1997-07-01 | Azdel, Inc. | Fiber reinforced functionalized polyolefin composites |
| US5457187A (en) | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
| DE4435728A1 (de) | 1994-01-19 | 1995-07-20 | Boehringer Mannheim Gmbh | Biotinsilan-Verbindungen und diese Verbindungen enthaltende Bindematrix |
| US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| CA2183431A1 (en) | 1994-02-22 | 1995-08-24 | Allan Svendsen | A method of preparing a variant of a lipolytic enzyme |
| US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
| HUT75368A (en) | 1994-05-11 | 1997-05-28 | Novo Nordisk As | An enzyme with endo-1,3(4)-beta-glucanase activity |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| HRP950288A2 (en) | 1994-05-31 | 1997-08-31 | Bayer Ag | Oxalylamino-benzofuran- and benzothienyl-derivatives |
| ES2127966T3 (es) | 1994-05-31 | 1999-05-01 | Bayer Ag | Derivados de amino-benzofurilo y -benzotienilo. |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| ATE202569T1 (de) | 1994-09-07 | 2001-07-15 | Hybridon Inc | Prodrug-oligonukleotide |
| US5681940A (en) | 1994-11-02 | 1997-10-28 | Icn Pharmaceuticals | Sugar modified nucleosides and oligonucleotides |
| AU4514696A (en) | 1994-12-22 | 1996-07-10 | Hybridon, Inc. | Synthesis of stereospecific oligonucleotide phosphorothioates |
| GB9501465D0 (en) | 1995-01-25 | 1995-03-15 | King S College London | Nucleoside phosphorothioate derivatives,synthesis and use thereof |
| DE69636160D1 (de) | 1995-03-06 | 2006-06-29 | Isis Pharmaceuticals Inc | Verfahren zur synthese von 2'-0-substituierten pyrimidinen und oligomere davon |
| US6166197A (en) | 1995-03-06 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
| DE69638104D1 (de) | 1995-04-27 | 2010-02-11 | Takara Bio Inc | Für Lacto-N-biosidase kodierendes Gen |
| ATE271128T1 (de) | 1995-05-11 | 2004-07-15 | Applied Research Systems | Inhibitoren der il-6 aktivitaet |
| CA2221589A1 (en) | 1995-05-19 | 1996-11-21 | Glycomed Incorporated | Collection of activated glycoside compounds and their biological use |
| AU5869696A (en) | 1995-05-23 | 1996-12-11 | Hybridon, Inc. | Novel synthons for stereoselective oligonucleotide synthesis |
| AU5871196A (en) | 1995-05-23 | 1996-12-24 | Hybridon, Inc. | Methods and compounds for the synthesis of oligonucleotides and the oligonucleotides thereby produced |
| AU698739B2 (en) | 1995-06-06 | 1998-11-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
| US5932450A (en) | 1995-06-07 | 1999-08-03 | Gen-Probe Incorporated | Enzymatic synthesis of oligonucleotides using digestible templates |
| US5824503A (en) | 1995-06-29 | 1998-10-20 | Takara Shuzo Co, Ltd. | Gene encoding endoglycoceramidase activator |
| EP0751222B1 (en) | 1995-06-29 | 2006-03-01 | Takara Bio Inc. | Gene encoding endoglycoceramidase |
| US6017700A (en) | 1995-08-04 | 2000-01-25 | Bayer Corporation | Cationic oligonucleotides, and related methods of synthesis and use |
| US5936080A (en) | 1996-05-24 | 1999-08-10 | Genta Incorporated | Compositions and methods for the synthesis of organophosphorus derivatives |
| WO1997009443A1 (en) | 1995-09-05 | 1997-03-13 | Michigan State University | PROCESS FOR THE ISOLATION AND PURIFICATION OF TAXOL AND TAXANES FROM TAXUS spp |
| US6476216B1 (en) | 1995-10-20 | 2002-11-05 | Mcgill University | Preparation of phosphorothioate oligomers |
| US6160109A (en) | 1995-10-20 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Preparation of phosphorothioate and boranophosphate oligomers |
| US5734041A (en) | 1995-10-20 | 1998-03-31 | Mcgill University | Preparation of chiral phosphorothioate oligomers |
| US7018793B1 (en) | 1995-12-07 | 2006-03-28 | Diversa Corporation | Combinatorial screening of mixed populations of organisms |
| US6214805B1 (en) | 1996-02-15 | 2001-04-10 | The United States Of America As Represented By The Department Of Health And Human Services | RNase L activators and antisense oligonucleotides effective to treat RSV infections |
| WO1997029757A1 (en) | 1996-02-15 | 1997-08-21 | National Institutes Of Health | Rnase l activators and antisense oligonucleotides effective to treat rsv infections |
| GB9604669D0 (en) | 1996-03-05 | 1996-05-01 | Ciba Geigy Ag | Chemical compounds |
| US5824669A (en) | 1996-03-22 | 1998-10-20 | Nitromed, Inc. | Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders |
| EP0898618B1 (en) | 1996-05-10 | 2007-10-31 | Novozymes A/S | Method of providing novel dna sequences |
| US5856465A (en) | 1996-05-24 | 1999-01-05 | Polska Akademia Nauk Centrum Badan Molekularnych I Makromolekularnych | Compositions and methods for the synthesis of chirally pure organophosphorus nucleoside derivatives |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US20080119427A1 (en) | 1996-06-06 | 2008-05-22 | Isis Pharmaceuticals, Inc. | Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation |
| DE19622783A1 (de) | 1996-06-07 | 1997-12-11 | Hoechst Ag | Isolierung der Biosynthesegene für Pseudo-Oligosaccharide aus Streptomyces glaucescens GLA.O und ihre Verwendung |
| EP0912767B1 (en) | 1996-07-16 | 2006-09-13 | Gen-Probe Incorporated | Methods for detecting and amplifying nucleic acid sequences using modified oligonucleotides having increased target specific tm |
| DE69734783T2 (de) | 1996-07-24 | 2006-08-17 | Buchardt, Dorte | Peptidnukleinsäuren mit erhöhter bindungsaffinität, sequenzspezifität und löslichkeit |
| WO1998007734A1 (en) | 1996-08-21 | 1998-02-26 | Hybridon, Inc. | Oligonucleotide prodrugs |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| GB9621522D0 (en) | 1996-10-16 | 1996-12-04 | Biocompatibles Ltd | Synthesis of phosphorus compounds |
| US6172209B1 (en) | 1997-02-14 | 2001-01-09 | Isis Pharmaceuticals Inc. | Aminooxy-modified oligonucleotides and methods for making same |
| US6639062B2 (en) | 1997-02-14 | 2003-10-28 | Isis Pharmaceuticals, Inc. | Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom |
| US6369237B1 (en) | 1997-03-07 | 2002-04-09 | President And Fellows Of Harvard College | DNA glycosylase inhibitors, and uses related thereto |
| US6015887A (en) | 1997-04-11 | 2000-01-18 | Isis Pharmaceuticals, Inc. | Chiral peptide nucleic acids and methods for preparing same |
| US6468983B2 (en) | 1997-04-21 | 2002-10-22 | The Cleveland Clinic Foundation | RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies |
| PL184612B1 (pl) | 1997-04-25 | 2002-11-29 | Pan | Sposób wytwarzania modyfikowanych P chiralnych analogów nukleotydów |
| NZ501289A (en) | 1997-05-28 | 2001-06-29 | Nielsen Peter E | Conjugated peptide nucleic acids having enhanced cellular uptake |
| WO1999000377A1 (en) | 1997-06-27 | 1999-01-07 | The Procter & Gamble Company | Pro-fragrance cyclic acetals |
| AU8512598A (en) | 1997-07-25 | 1999-02-16 | Hybridon, Inc. | Oligonuclotides having 3' terminal stereospecific phosphorothioates |
| US6767739B2 (en) | 2001-07-30 | 2004-07-27 | Isis Pharmaceuticals Inc. | Antisense modulation of microsomal triglyceride transfer protein expression |
| US6383808B1 (en) | 2000-09-11 | 2002-05-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of clusterin expression |
| GB9717158D0 (en) | 1997-08-13 | 1997-10-22 | King S College London | Solution synthesis of oligonucleotides and their phosphorothioate analogues |
| US6750344B1 (en) | 1997-09-05 | 2004-06-15 | Isis Pharmaceuticals, Inc. | Amine compounds and combinatorial libraries comprising same |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| DE19741715A1 (de) | 1997-09-22 | 1999-03-25 | Hoechst Ag | Pentopyranosyl-Nucleosid, seine Herstellung und Verwendung |
| US6232463B1 (en) | 1997-10-09 | 2001-05-15 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
| US6528640B1 (en) | 1997-11-05 | 2003-03-04 | Ribozyme Pharmaceuticals, Incorporated | Synthetic ribonucleic acids with RNAse activity |
| US6617438B1 (en) | 1997-11-05 | 2003-09-09 | Sirna Therapeutics, Inc. | Oligoribonucleotides with enzymatic activity |
| US6080543A (en) | 1997-12-08 | 2000-06-27 | E. & J. Gallo Winery | Detection of fungal pathogens |
| US6582936B1 (en) | 1997-12-12 | 2003-06-24 | The Regents Of The University Of California | Methods for making nucleic acids |
| US6248519B1 (en) | 1998-03-11 | 2001-06-19 | E & J Gallo Winery | Detection of fermentation-related microorganisms |
| US7045610B2 (en) | 1998-04-03 | 2006-05-16 | Epoch Biosciences, Inc. | Modified oligonucleotides for mismatch discrimination |
| EP1077708A1 (en) | 1998-05-06 | 2001-02-28 | University Of Iowa Research Foundation | Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides |
| AU760795B2 (en) | 1998-05-14 | 2003-05-22 | Coley Pharmaceutical Gmbh | Methods for regulating hematopoiesis using CpG-oligonucleotides |
| US6242589B1 (en) * | 1998-07-14 | 2001-06-05 | Isis Pharmaceuticals, Inc. | Phosphorothioate oligonucleotides having modified internucleoside linkages |
| US6867294B1 (en) | 1998-07-14 | 2005-03-15 | Isis Pharmaceuticals, Inc. | Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages |
| JP2002521489A (ja) | 1998-07-27 | 2002-07-16 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | CpGオリゴヌクレオチドの立体異性体および関連する方法 |
| ATE315405T1 (de) | 1998-08-10 | 2006-02-15 | Antigenics Inc | Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung |
| WO2000023444A1 (en) | 1998-10-21 | 2000-04-27 | Abbott Laboratories | 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds |
| US6995259B1 (en) | 1998-10-23 | 2006-02-07 | Sirna Therapeutics, Inc. | Method for the chemical synthesis of oligonucleotides |
| AU1742600A (en) | 1998-11-25 | 2000-06-13 | Isis Pharmaceuticals, Inc. | Identification of disease predictive nucleic acids |
| US6451524B1 (en) | 1998-11-25 | 2002-09-17 | Isis Pharmaceuticals, Inc. | Identification of disease predictive nucleic acids |
| WO2000040749A2 (en) | 1999-01-06 | 2000-07-13 | Genenews Inc. | Method for the detection of gene transcripts in blood and uses thereof |
| US6265172B1 (en) | 1999-02-08 | 2001-07-24 | University Of Kentucky | Diagnostic test and therapy for manganese superoxide dismutate (mNsod) associated diseases |
| US6121437A (en) | 1999-03-16 | 2000-09-19 | Isis Pharmaceuticals, Inc. | Phosphate and thiophosphate protecting groups |
| US6506594B1 (en) | 1999-03-19 | 2003-01-14 | Cornell Res Foundation Inc | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
| GB9907245D0 (en) | 1999-03-29 | 1999-05-26 | Goldsborough Andrew | Cleavage of nucleic acids from solid supports |
| JP3072345B1 (ja) | 1999-03-31 | 2000-07-31 | 農林水産省家畜衛生試験場長 | 豚丹毒菌の組換えサブユニットワクチン |
| US5998148A (en) | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| US6300069B1 (en) | 1999-05-03 | 2001-10-09 | Qiagen Gmbh | Generation and amplification of nucleic acids from ribonucleic acids |
| US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
| US6271004B1 (en) | 1999-06-25 | 2001-08-07 | Display Systems Biotech A/S | Method for improved reverse transcription at high temperatures |
| US6066500A (en) | 1999-06-25 | 2000-05-23 | Isis Pharmaceuticals Inc. | Antisense modulation of Beta catenin expression |
| US6414135B1 (en) | 1999-07-07 | 2002-07-02 | Isis Pharmaceuticals, Inc. | C3′-methylene hydrogen phosphonate monomers and related compounds |
| US20030092647A1 (en) | 2001-08-08 | 2003-05-15 | Crooke Rosanne M. | Antisense modulation of cholesteryl ester transfer protein expression |
| US6147200A (en) | 1999-08-19 | 2000-11-14 | Isis Pharmaceuticals, Inc. | 2'-O-acetamido modified monomers and oligomers |
| US7264932B2 (en) | 1999-09-24 | 2007-09-04 | Applera Corporation | Nuclease inhibitor cocktail |
| WO2001022972A2 (en) | 1999-09-25 | 2001-04-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
| US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
| IL148844A0 (en) | 1999-09-27 | 2002-09-12 | Coley Pharm Group Inc | Methods related to immunostimulatory nucleic acid-induced interferon |
| US20020082227A1 (en) | 1999-09-30 | 2002-06-27 | Scott Henry | Use of oligonucleotides for inhibition of complement activation |
| US6528262B1 (en) | 1999-10-06 | 2003-03-04 | Quark Biotech, Inc. | Method for enrichment of natural antisense messenger RNA |
| GB9924285D0 (en) | 1999-10-14 | 1999-12-15 | Avecia Ltd | Process |
| US20010055761A1 (en) | 1999-10-29 | 2001-12-27 | Agilent Technologies | Small scale dna synthesis using polymeric solid support with functionalized regions |
| FR2800750B1 (fr) | 1999-11-05 | 2003-01-31 | Centre Nat Rech Scient | Proteines membranaires ctl (choline transporter like) impliquees dans le transport de la choline |
| AU1656601A (en) | 1999-11-12 | 2001-06-12 | Isis Pharmaceuticals, Inc. | Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages |
| US6322985B1 (en) | 1999-12-27 | 2001-11-27 | Technion Research And Development Foundation Ltd. | Abundant, well distributed and hyperpolymorphic simple sequence repeats in prokaryote genomes and use of same for prokaryote classification and typing |
| US7055094B2 (en) | 1999-12-30 | 2006-05-30 | Rutgers, The State University Of New Jersey | Virtual tags and the process of virtual tagging utilizing user feedback in transformation rules |
| AU2743801A (en) | 1999-12-30 | 2001-07-16 | Cabot Corporation | Sensors with improved properties |
| US6649750B1 (en) | 2000-01-05 | 2003-11-18 | Isis Pharmaceuticals, Inc. | Process for the preparation of oligonucleotide compounds |
| US6159697A (en) | 2000-01-19 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad7 expression |
| US7585847B2 (en) | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
| US6495677B1 (en) | 2000-02-15 | 2002-12-17 | Kanda S. Ramasamy | Nucleoside compounds |
| EP1130091A3 (en) | 2000-03-01 | 2001-11-14 | Message Pharmaceuticals, Inc. | Bacterial RNaseP Proteins and their use in identifying antibacterial compounds |
| GB0004889D0 (en) | 2000-03-01 | 2000-04-19 | Avecia Ltd | Synthesis of oligonucleotides |
| JP2003528068A (ja) | 2000-03-17 | 2003-09-24 | コリクサ コーポレイション | 新規両親媒性アルデヒドならびにアジュバントおよび免疫エフェクターとしてのそれらの使用 |
| JP4219590B2 (ja) | 2000-04-20 | 2009-02-04 | エフ.ホフマン−ラ ロシュ アーゲー | ピロリジン及びピペリジン誘導体並びに神経変性障害の治療のためのこれらの使用 |
| DE10019756A1 (de) | 2000-04-20 | 2001-10-25 | Bayer Ag | Verfahren zur Herstellung von superabsorbierenden Polymeren aus Polyacrylnitrilen |
| WO2001085751A1 (en) | 2000-05-09 | 2001-11-15 | Reliable Biopharmaceutical, Inc. | Polymeric compounds useful as prodrugs |
| US6492171B2 (en) | 2000-05-16 | 2002-12-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of TERT expression |
| US6815542B2 (en) | 2000-06-16 | 2004-11-09 | Ribapharm, Inc. | Nucleoside compounds and uses thereof |
| US7238795B2 (en) | 2000-08-03 | 2007-07-03 | Roche Molecular Systems, Inc. | Nucleic acid binding compounds containing pyrazolo[3,4-d]pyrimidine analogues of purin-2,6-diamine and their uses |
| US6725412B1 (en) | 2000-08-15 | 2004-04-20 | Dolby Laboratories Licensing Corporation | Low latency data encoder |
| US6809195B1 (en) | 2000-08-16 | 2004-10-26 | Isis Pharmaceuticals, Inc. | Process for the preparation of oligonucleotides |
| US6559279B1 (en) | 2000-09-08 | 2003-05-06 | Isis Pharmaceuticals, Inc. | Process for preparing peptide derivatized oligomeric compounds |
| EP1366077B1 (en) | 2000-09-15 | 2011-05-25 | Coley Pharmaceutical GmbH | PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST |
| EP1191097A1 (en) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
| GB0024752D0 (en) | 2000-10-10 | 2000-11-22 | Univ Belfast | Oxidative halogenation of aromatic compounds |
| IL155282A0 (en) | 2000-10-18 | 2003-11-23 | Glaxosmithkline Biolog Sa | Vaccines |
| US6372492B1 (en) | 2000-10-30 | 2002-04-16 | Isis Pharmaceuticals, Inc. | Antisense modulation of talin expression |
| US6682889B1 (en) | 2000-11-08 | 2004-01-27 | Becton, Dickinson And Company | Amplification and detection of organisms of the Chlamydiaceae family |
| NL1016978C2 (nl) | 2000-12-22 | 2002-06-25 | Robert Jan Colenbrander | Inrichting en werkwijze voor het verpakken en bereiden van voedsel en werkwijze voor het vervaardigen van een dergelijke inrichting. |
| MXPA03006514A (es) | 2001-01-22 | 2004-12-02 | Merck & Co Inc | Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico. |
| WO2002059297A2 (en) | 2001-01-25 | 2002-08-01 | Evolva Biotech A/S | A library of a collection of cells |
| US8008459B2 (en) | 2001-01-25 | 2011-08-30 | Evolva Sa | Concatemers of differentially expressed multiple genes |
| JP4454934B2 (ja) | 2001-01-26 | 2010-04-21 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション | 組換えクローニングを用いて効率のよいサイレンシング構築物を作製する方法および手段 |
| US20050277133A1 (en) | 2001-05-18 | 2005-12-15 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
| US20030207804A1 (en) | 2001-05-25 | 2003-11-06 | Muthiah Manoharan | Modified peptide nucleic acids |
| GB0113523D0 (en) | 2001-06-04 | 2001-07-25 | Torotrak Dev Ltd | An Hydraulic control circuit for a continuosly variable transmission |
| US20030069410A1 (en) * | 2001-06-14 | 2003-04-10 | Isis Pharmaceuticals, Inc. | Methods for preparing oligonucleotides having chiral phosphorothioate linkages |
| US20050019915A1 (en) | 2001-06-21 | 2005-01-27 | Bennett C. Frank | Antisense modulation of superoxide dismutase 1, soluble expression |
| AU2002322358B2 (en) | 2001-06-29 | 2009-06-18 | Novartis Vaccines And Diagnostics, Inc. | HCV E1E2 vaccine compositions |
| JP2005504020A (ja) | 2001-07-03 | 2005-02-10 | アイシス・ファーマシューティカルス・インコーポレーテッド | ヌクレアーゼ耐性キメラオリゴヌクレオチド |
| US7205399B1 (en) | 2001-07-06 | 2007-04-17 | Sirna Therapeutics, Inc. | Methods and reagents for oligonucleotide synthesis |
| US6440739B1 (en) | 2001-07-17 | 2002-08-27 | Isis Pharmaceuticals, Inc. | Antisense modulation of glioma-associated oncogene-2 expression |
| US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
| US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| US6455308B1 (en) | 2001-08-01 | 2002-09-24 | Isis Pharmaceuticals, Inc. | Antisense modulation of serum amyloid A4 expression |
| US7888324B2 (en) | 2001-08-01 | 2011-02-15 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
| US7259150B2 (en) | 2001-08-07 | 2007-08-21 | Isis Pharmaceuticals, Inc. | Modulation of apolipoprotein (a) expression |
| US7354909B2 (en) | 2001-08-14 | 2008-04-08 | The United States Of America As Represented By Secretary Of The Department Of Health And Human Services | Method for rapid generation of mature dendritic cells |
| CA2458393A1 (en) | 2001-08-24 | 2003-03-06 | Massachusetts Institute Of Technology | Reagents that facilitate the purification of compounds synthesized on a solid support |
| US7049122B2 (en) | 2001-09-21 | 2006-05-23 | Academia Sinica | Mutant-type lipases and applications thereof |
| US6933288B2 (en) | 2002-02-04 | 2005-08-23 | Isis Pharmaceuticals, Inc. | Pyranosyl cytosines: pharmaceutical formulations and methods |
| JP4348044B2 (ja) | 2002-02-12 | 2009-10-21 | 株式会社キラルジェン | 立体規則性の高いジヌクレオシドホスホロチオエートの製造法 |
| US20030159938A1 (en) | 2002-02-15 | 2003-08-28 | George Hradil | Electroplating solution containing organic acid complexing agent |
| US20040149587A1 (en) | 2002-02-15 | 2004-08-05 | George Hradil | Electroplating solution containing organic acid complexing agent |
| US20050096284A1 (en) | 2002-02-20 | 2005-05-05 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
| US8232383B2 (en) | 2002-02-20 | 2012-07-31 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| RU2004128943A (ru) | 2002-02-28 | 2005-04-20 | Байота, Инк. (Us) | Средства, имитирующие нуклеотиды, и их пролекарственные формы |
| WO2003073989A2 (en) | 2002-02-28 | 2003-09-12 | Biota, Inc. | Nucleoside 5'-monophosphate mimics and their prodrugs |
| US7288376B2 (en) | 2002-03-22 | 2007-10-30 | Council Of Scientific And Industrial Research | Method of detection of SP-A2 gene variants useful for prediction of predisposition to aspergillosis |
| US20040102394A1 (en) | 2002-11-23 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of huntingtin interacting protein 2 expression |
| US7247621B2 (en) | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
| WO2003097662A1 (en) | 2002-05-15 | 2003-11-27 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein b expression |
| WO2003099840A1 (en) | 2002-05-24 | 2003-12-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides having modified nucleoside units |
| US20040014108A1 (en) | 2002-05-24 | 2004-01-22 | Eldrup Anne B. | Oligonucleotides having modified nucleoside units |
| US7507808B2 (en) | 2002-12-12 | 2009-03-24 | Isis Pharmaceuticals, Inc. | Modulation of endothelial lipase expression |
| WO2003106477A1 (en) | 2002-06-01 | 2003-12-24 | Isis Pharmaceuticals, Inc. | Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation |
| ATE489969T1 (de) | 2002-06-20 | 2010-12-15 | Cytos Biotechnology Ag | Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung |
| WO2004003228A1 (en) | 2002-07-01 | 2004-01-08 | Unisearch Limited | Genotyping method |
| CA2489174C (en) | 2002-07-10 | 2013-02-05 | Thomas Tuschl | Rna-interference by single-stranded rna molecules |
| US20040023905A1 (en) | 2002-07-31 | 2004-02-05 | Isis Pharmaceuticals Inc. | Antisense modulation of LAR expression |
| US20080274989A1 (en) | 2002-08-05 | 2008-11-06 | University Of Iowa Research Foundation | Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof |
| US20050042646A1 (en) | 2002-08-05 | 2005-02-24 | Davidson Beverly L. | RNA interference suppresion of neurodegenerative diseases and methods of use thereof |
| US20050255086A1 (en) | 2002-08-05 | 2005-11-17 | Davidson Beverly L | Nucleic acid silencing of Huntington's Disease gene |
| AU2003261449A1 (en) | 2002-08-07 | 2004-02-25 | Compositions for rna interference and methods of use thereof | |
| AU2003259735A1 (en) | 2002-08-08 | 2004-02-25 | Sirna Therapeutics, Inc. | Small-mer compositions and methods of use |
| AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
| US7414116B2 (en) | 2002-08-23 | 2008-08-19 | Illumina Cambridge Limited | Labelled nucleotides |
| EA008940B1 (ru) | 2002-09-13 | 2007-10-26 | Репликор, Инк. | Антивирусные олигонуклеотиды, не связанные с комплементарностью последовательностей |
| US7030230B2 (en) | 2002-10-25 | 2006-04-18 | Isis Pharmaceuticals, Inc. | Process of purifying phosphoramidites |
| NZ540098A (en) | 2002-10-29 | 2008-09-26 | Coley Pharmaceutical Group Ltd | Use of CPG oligonucleotides in the treatment of hepatitis C virus infection |
| AU2003291721A1 (en) | 2002-11-05 | 2004-06-03 | Isis Pharmaceuticals, Inc. | Phosphorous-linked oligomeric compounds and their use in gene modulation |
| US8604183B2 (en) | 2002-11-05 | 2013-12-10 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
| CA2504694C (en) | 2002-11-05 | 2013-10-01 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| CA2505090A1 (en) | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Conjugated oligomeric compounds and their use in gene modulation |
| US7381527B2 (en) | 2002-11-06 | 2008-06-03 | Council Of Scientific And Industrial Research | Method of detection of SP-A2 gene variants |
| AU2003294281B2 (en) | 2002-11-13 | 2010-05-20 | Kastle Therapeutics, Llc | Antisense modulation of apolipoprotein B expression |
| US7511131B2 (en) | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| EP2305813A3 (en) | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| CA2518475C (en) | 2003-03-07 | 2014-12-23 | Alnylam Pharmaceuticals, Inc. | Irna agents comprising asymmetrical modifications |
| WO2004080466A1 (en) | 2003-03-07 | 2004-09-23 | Ribapharm Inc. | Cytidine analogs and methods of use |
| AU2003225410A1 (en) | 2003-03-21 | 2004-10-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| GB0306657D0 (en) | 2003-03-24 | 2003-04-30 | Avecia Ltd | Process and compounds |
| US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
| CN101675993A (zh) | 2003-03-26 | 2010-03-24 | 赛托斯生物技术公司 | Melan-a肽类似物-病毒样颗粒偶联物 |
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| US20050261237A1 (en) | 2003-04-25 | 2005-11-24 | Boojamra Constantine G | Nucleoside phosphonate analogs |
| US7407965B2 (en) | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
| EP1617848A2 (en) | 2003-04-25 | 2006-01-25 | Gilead Sciences, Inc. | Anti-cancer phosphonate conjugates |
| US7470724B2 (en) | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
| SG182849A1 (en) | 2003-04-25 | 2012-08-30 | Gilead Sciences Inc | Antiviral phosphonate analogs |
| WO2004096233A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Nucleoside phosphonate conjugates |
| CN101410120A (zh) | 2003-04-25 | 2009-04-15 | 吉里德科学公司 | 抗炎的膦酸酯化合物 |
| WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
| US7432261B2 (en) | 2003-04-25 | 2008-10-07 | Gilead Sciences, Inc. | Anti-inflammatory phosphonate compounds |
| US20090247488A1 (en) | 2003-04-25 | 2009-10-01 | Carina Cannizzaro | Anti-inflammatory phosphonate compounds |
| US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
| US7045306B2 (en) | 2003-04-28 | 2006-05-16 | The General Hospital Corporation | Method for identifying compounds in vitro that modulate the dysregulation of transcription of transcription mediated by mutant huntingtin protein |
| US7214491B2 (en) | 2003-05-07 | 2007-05-08 | E. I. Du Pont De Nemours And Company | Δ-12 desaturase gene suitable for altering levels of polyunsaturated fatty acids in oleaginous yeasts |
| AU2004239114B2 (en) | 2003-05-14 | 2008-03-13 | Japan Science And Technology Agency | Inhibition of the expression of huntingtin gene |
| JP4579911B2 (ja) | 2003-06-03 | 2010-11-10 | アイシス・ファーマシューティカルズ・インコーポレイテッド | スルビビン発現の調節 |
| US7410975B2 (en) | 2003-06-20 | 2008-08-12 | Coley Pharmaceutical Group, Inc. | Small molecule toll-like receptor (TLR) antagonists |
| WO2005013901A2 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| JP2005089441A (ja) | 2003-08-08 | 2005-04-07 | Toudai Tlo Ltd | 立体規則性の高いリン原子修飾ヌクレオチド類縁体の製造法 |
| JP2011088935A (ja) | 2003-08-08 | 2011-05-06 | Chiralgen Ltd | リン原子修飾ヌクレオチド類縁体の製造のための光学活性ヌクレオシド3’−ホスホロアミダイト |
| US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
| MXPA06001976A (es) | 2003-08-21 | 2006-05-31 | Univ Griffith | Nuevas sulfenamidas. |
| MXPA06001974A (es) | 2003-08-21 | 2006-05-31 | Univ Griffith | Nuevos oxidos de sulfenamida. |
| WO2005021568A2 (en) | 2003-08-27 | 2005-03-10 | Biota, Inc. | Novel tricyclic nucleosides or nucleotides as therapeutic agents |
| DK1661905T3 (da) | 2003-08-28 | 2012-07-23 | Takeshi Imanishi | Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype |
| JP4580870B2 (ja) | 2003-09-02 | 2010-11-17 | 株式会社キラルジェン | リボヌクレオチド又はリボヌクレオチド誘導体の製造方法 |
| JP4616175B2 (ja) | 2003-09-02 | 2011-01-19 | 株式会社キラルジェン | 5’−ホスフィチル化モノマーおよびh−ホスホネートオリゴヌクレオチド誘導体の製造方法 |
| DK3342425T3 (da) | 2003-09-09 | 2020-03-16 | Geron Corp | Modificerede oligonukleotider til inhibering af telomerase |
| US20050053981A1 (en) | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
| US20050074801A1 (en) | 2003-09-09 | 2005-04-07 | Monia Brett P. | Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry |
| WO2005027980A1 (en) | 2003-09-12 | 2005-03-31 | University Of Massachusetts | Rna interference for the treatment of gain-of-function disorders |
| US8680063B2 (en) | 2003-09-12 | 2014-03-25 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
| GB0323968D0 (en) | 2003-10-13 | 2003-11-19 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
| NZ546275A (en) | 2003-10-30 | 2009-05-31 | Coley Pharm Gmbh | C-class oligonucleotides analogs with enhanced immunostimulatory potency |
| US20050239102A1 (en) | 2003-10-31 | 2005-10-27 | Verdine Gregory L | Nucleic acid binding oligonucleotides |
| US7846436B2 (en) | 2003-11-28 | 2010-12-07 | Chemgenes Corporation | Oligonucleotides and related compounds |
| AU2003300239A1 (en) | 2003-12-29 | 2005-07-21 | Galapagos Genomics N.V. | Modulators of bone homeostasis identified in a high-throughput screen |
| JP4945129B2 (ja) | 2004-01-27 | 2012-06-06 | 株式会社キラルジェン | フルオラス担体およびそれを用いたオリゴヌクレオチド誘導体の製造方法 |
| US20050176045A1 (en) | 2004-02-06 | 2005-08-11 | Dharmacon, Inc. | SNP discriminatory siRNA |
| US20080221303A1 (en) | 2004-02-18 | 2008-09-11 | Jehoshua Katzhendler | Method for the Preparation of Peptide-Oligonucleotide Conjugates |
| JP3976742B2 (ja) | 2004-02-27 | 2007-09-19 | 江守商事株式会社 | インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド |
| WO2005085272A1 (ja) | 2004-03-05 | 2005-09-15 | Takeshi Wada | ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法 |
| WO2005092909A1 (ja) | 2004-03-25 | 2005-10-06 | Toudai Tlo, Ltd. | 立体規則性の高いリボヌクレオチド類縁体及びデオキシリボヌクレオチド類縁体の製造法 |
| EP2540734B1 (en) | 2004-04-05 | 2016-03-30 | Alnylam Pharmaceuticals, Inc. | Process and reagents for oligonucleotide synthesis and purification |
| US20050244869A1 (en) | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
| TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
| WO2005116268A2 (en) | 2004-05-27 | 2005-12-08 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health | Differential expression of molecules associated with acute stroke |
| US7759318B1 (en) | 2004-05-28 | 2010-07-20 | Isis Pharmaceuticals, Inc. | Identification of novel pathways, genes and promoter motifs regulating adipogenesis |
| ES2627917T3 (es) | 2004-06-28 | 2017-08-01 | The University Of Western Australia | Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos |
| SI2409713T1 (sl) | 2004-08-10 | 2015-10-30 | Genzyme Corporation | Oligonukleotidi za uporabo pri uravnavanju nivojev lipoproteinov in holesterola pri ljudeh |
| ATE556085T1 (de) | 2004-08-26 | 2012-05-15 | Nippon Shinyaku Co Ltd | Phosphoramiditverbindung und verfahren zur herstellung von oligo-rna |
| AU2005282380A1 (en) | 2004-09-07 | 2006-03-16 | Archemix Corp. | Aptamer medicinal chemistry |
| US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
| WO2006031461A2 (en) | 2004-09-09 | 2006-03-23 | Isis Pharmaceuticals, Inc. | Pyrrolidinyl groups for attaching conjugates to oligomeric compounds |
| EP1799859B1 (en) | 2004-09-17 | 2014-07-02 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
| US20060089325A1 (en) | 2004-10-13 | 2006-04-27 | Sanjay Bhanot | Antisense modulation of PTP1B expression |
| US9120774B2 (en) | 2004-11-03 | 2015-09-01 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| AU2005301957B2 (en) | 2004-11-03 | 2012-02-23 | Department Of Health And Human Services | Novobiocin analogues as anticancer agents |
| US8212011B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues |
| US8212012B2 (en) | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| US7622451B2 (en) | 2004-11-03 | 2009-11-24 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| KR100721928B1 (ko) | 2004-11-05 | 2007-05-28 | 주식회사 바이오씨에스 | CpG 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물 |
| EP1657307A1 (en) | 2004-11-16 | 2006-05-17 | Immunotech S.A. | Oligonucleotides that induce the secretion of GM-CSF |
| WO2006063252A2 (en) | 2004-12-09 | 2006-06-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering rnas |
| WO2006065751A2 (en) | 2004-12-13 | 2006-06-22 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods |
| WO2006066260A2 (en) | 2004-12-17 | 2006-06-22 | Thiosense, Inc. | Compositions of and methods for producing phosphorus-chiral monomers and oligomers |
| US20070099851A1 (en) | 2004-12-30 | 2007-05-03 | Linn Gregory S | Stable analogues of ribose-1-phosphate and methods for treating diabetes and other metabolic disorders |
| US20060183763A1 (en) | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
| JP4836145B2 (ja) | 2005-01-28 | 2011-12-14 | クウォン,ヒュン−ジョ | マイコバクテリアに由来する、免疫機能刺激用、免疫疾患治療用、アトピー性皮膚炎治療用および/または正常免疫細胞保護用オリゴヌクレオチド |
| WO2006091915A2 (en) | 2005-02-24 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
| JP5242375B2 (ja) | 2005-04-01 | 2013-07-24 | ザ レゲントス オブ ザ ユニバーシティ オブ カリフォルニア | ホスホノ−ペント−2−エン−1−イルヌクレオシド及び類似体 |
| MX2007007184A (es) | 2005-05-05 | 2008-01-14 | Antisense Pharma Gmbh | Uso de bajas dosis de oligonucleotidos antisentido para tgf-beta, vegf, interleucina-10, c-jun, c-fos o genes e2 de prostaglandina en el tratamiento de tumores. |
| US20060257912A1 (en) | 2005-05-06 | 2006-11-16 | Medtronic, Inc. | Methods and sequences to suppress primate huntington gene expression |
| US7902352B2 (en) | 2005-05-06 | 2011-03-08 | Medtronic, Inc. | Isolated nucleic acid duplex for reducing huntington gene expression |
| PT2548560E (pt) | 2005-06-23 | 2015-09-22 | Isis Pharmaceuticals Inc | Composições e métodos de modulação da excisão-união de smn2 |
| ATE522626T1 (de) | 2005-06-28 | 2011-09-15 | Medtronic Inc | Verfahren und nukleotid-sequenzen, die bevorzugt die expression eines mutierten huntingtin-genes unterdrücken |
| US9133517B2 (en) | 2005-06-28 | 2015-09-15 | Medtronics, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin |
| WO2007005941A2 (en) | 2005-07-05 | 2007-01-11 | President And Fellows Of Harvard College | Liver targeted conjugates |
| JP4984634B2 (ja) | 2005-07-21 | 2012-07-25 | ソニー株式会社 | 物理情報取得方法および物理情報取得装置 |
| BRPI0615958B8 (pt) | 2005-07-28 | 2021-05-25 | Id Fish Tech Inc | composição para aumentar a permeabilidade de paredes celulares e membranas celulares de mycobacterium sp. e método para detectar um alvo em uma célula |
| ATE494372T1 (de) | 2005-08-29 | 2011-01-15 | Regulus Therapeutics Inc | Verfahren für mir-122a-modulation |
| WO2007028065A2 (en) | 2005-08-30 | 2007-03-08 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds for modulation of splicing |
| US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| US20070077993A1 (en) | 2005-09-30 | 2007-04-05 | Midgley Timothy M | Method and apparatus for collecting user game play data and crediting users in a gaming environment |
| ES2544877T3 (es) | 2005-10-12 | 2015-09-04 | Idera Pharmaceuticals | Compuestos oligonucleótidos inmuno reguladores (IRO) para modular la respuesta inmune basada en receptor semejante a Toll |
| US9308252B2 (en) | 2005-10-27 | 2016-04-12 | Cook Biotech, Inc. | Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins |
| EP2325315B1 (en) | 2005-10-28 | 2014-05-07 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of huntingtin gene |
| EP2471919A1 (en) | 2005-10-28 | 2012-07-04 | Tosoh Corporation | Method of preparing carotenoid synthesizing microorganism and method of producing carotenoids |
| KR20080075107A (ko) | 2005-11-11 | 2008-08-14 | 화이자 인코포레이티드 | 면역조절성 올리고데옥시뉴클레오티드를 사용하는 조합물및 방법 |
| WO2007064291A1 (en) | 2005-11-30 | 2007-06-07 | Jyoti Chattopadhyaya | Method and compounds for rna synthesis |
| AU2006320374B2 (en) | 2005-12-02 | 2012-08-30 | Isis Pharmaceuticals, Inc. | Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents |
| US8076303B2 (en) * | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
| MY151455A (en) | 2005-12-21 | 2014-05-30 | Pfizer Prod Inc | Carbonylamino pyrrolopyrazoles, potent kinase inhibitors |
| EP2422819B1 (en) | 2006-01-26 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Compositions and their uses directed to Huntingtin |
| DE602007009487D1 (de) | 2006-01-27 | 2010-11-11 | Isis Pharmaceutical Inc | 6-modifizierte bicyclische nukleinsäureanaloga |
| WO2007095316A2 (en) | 2006-02-15 | 2007-08-23 | Coley Pharmaceutical Gmbh | Compositions and methods for oligonucleotide formulations |
| US7759470B2 (en) | 2006-02-20 | 2010-07-20 | Roche Diagnostics Operations, Inc. | Labeling reagent |
| US8383660B2 (en) | 2006-03-10 | 2013-02-26 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
| WO2007115265A2 (en) | 2006-03-31 | 2007-10-11 | Applied Biosystems Inc. | Reagents useful for synthesizing rhodamine-labeled oligonucleotides |
| US8088582B2 (en) | 2006-04-06 | 2012-01-03 | Ibis Biosciences, Inc. | Compositions for the use in identification of fungi |
| KR101176697B1 (ko) | 2006-04-20 | 2012-08-23 | 에프. 호프만-라 로슈 아게 | 케모카인 수용체의 다이아제판 유도체 조절자 |
| DK2020449T3 (da) | 2006-04-24 | 2013-01-14 | Sigma Alimentos Sa De Cv | Fremgangsmåde til detektion og multipel, simultan kvantificering af patogener ved hjælp af real-time polymerasekædereaktion |
| US20130129752A1 (en) | 2006-04-25 | 2013-05-23 | Immune Disease Institute, Inc. | Targeted delivery to leukocytes using protein carriers |
| GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
| EP2505646A1 (en) | 2006-05-05 | 2012-10-03 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of CRP |
| EP2023936A4 (en) | 2006-05-05 | 2010-11-24 | Isis Pharmaceuticals Inc | COMPOSITIONS AND THEIR USES ASSOCIATED WITH THE ALPHA PTPR RECEPTOR |
| US20090012120A1 (en) | 2006-05-10 | 2009-01-08 | Board Of Trustees Of Michigan State University | Synthesis of N-heterocycles, beta-amino acids, and allyl amines via aza-payne mediated reaction of ylides and hydroxy aziridines |
| CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
| DK2034015T3 (da) | 2006-05-31 | 2012-10-15 | Toray Industries | Immunstimulerende oligonucleotid og farmaceutisk anvendelse heraf |
| US8097596B2 (en) | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
| EP2046993A4 (en) | 2006-07-07 | 2010-11-17 | Univ Massachusetts | RNA SILENCING COMPOSITIONS, AND METHODS OF TREATING HUNTINGTON CHOREA |
| EP2046964B1 (en) | 2006-07-12 | 2018-07-04 | The Regents of The University of California | Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups |
| EP2051977A2 (en) | 2006-07-20 | 2009-04-29 | Amgen Inc. | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1 |
| GB0614947D0 (en) | 2006-07-27 | 2006-09-06 | Isis Innovation | Epitope reduction therapy |
| WO2008017081A1 (en) | 2006-08-04 | 2008-02-07 | Isis Pharmaceuticals, Inc. | Compositions and methods for the modulation of jnk proteins |
| AT504194B1 (de) | 2006-09-07 | 2008-07-15 | Oesterr Rotes Kreuz | Bakteriennachweis |
| US8138330B2 (en) | 2006-09-11 | 2012-03-20 | Sigma-Aldrich Co. Llc | Process for the synthesis of oligonucleotides |
| MX2009003398A (es) | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada. |
| EP2410053B2 (en) | 2006-10-18 | 2020-07-15 | Ionis Pharmaceuticals, Inc. | Antisense compounds |
| JP2010507681A (ja) | 2006-10-23 | 2010-03-11 | アイアールエム・リミテッド・ライアビリティ・カンパニー | カテプシンプロテアーゼ阻害剤 |
| EP2104738A2 (en) | 2006-10-26 | 2009-09-30 | Coley Pharmaceuticals GmbH | Oligoribonucleotides and uses thereof |
| FR2908414B1 (fr) | 2006-11-13 | 2012-01-20 | Centre Nat Rech Scient | Immobilisation de proteines membranaires sur un support par l'intermediaire d'une molecule amphiphile |
| MX2009005252A (es) | 2006-11-17 | 2009-05-28 | Abbott Lab | Aminopirrolidinas como antagonistas del receptor de quimiocina. |
| EA200900741A1 (ru) | 2006-11-27 | 2010-04-30 | Айзис Фармасьютикалз, Инк. | Способы лечения гиперхолестеринемии |
| US8093222B2 (en) | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| EP2079305A4 (en) | 2006-12-12 | 2010-01-27 | Idera Pharmaceuticals Inc | SYNTHETIC AGONISTS OF TLR9 |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| US20100190837A1 (en) | 2007-02-15 | 2010-07-29 | Isis Pharmaceuticals, Inc. | 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom |
| US9347061B2 (en) | 2007-03-24 | 2016-05-24 | Genzyme Corporation | Administering antisense oligonucleotides complementary to human apolipoprotein B |
| US7960353B2 (en) | 2007-05-10 | 2011-06-14 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
| JP5646320B2 (ja) | 2007-05-11 | 2014-12-24 | アダイニクス, インコーポレイテッド | 遺伝子発現と疼痛 |
| JP5322927B2 (ja) | 2007-05-24 | 2013-10-23 | 杏林製薬株式会社 | 14位置換基に複素芳香環カルボン酸構造を有するムチリン誘導体 |
| GB0710186D0 (en) | 2007-05-29 | 2007-07-04 | Texas Instr Denmark | PWM loop with minimum allasing error property |
| DK2170917T3 (da) | 2007-05-30 | 2012-10-08 | Isis Pharmaceuticals Inc | N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro |
| AU2008258599B2 (en) | 2007-06-05 | 2013-06-13 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission |
| WO2008154401A2 (en) | 2007-06-08 | 2008-12-18 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| WO2008151833A2 (en) | 2007-06-13 | 2008-12-18 | Hochschule Mannheim | Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds |
| DE602007005629D1 (de) | 2007-06-18 | 2010-05-12 | Commissariat Energie Atomique | Reversibles siRNA-Silencing eines mutierten und endogenen Huntington-Wildtypgens und dessen Anwendung zur Behandlung von Morbus Huntington |
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| KR101343489B1 (ko) | 2007-07-09 | 2013-12-20 | 이데라 파마슈티칼즈, 인코포레이티드 | 안정화된 면역 조절성 rna(simra)화합물 |
| TWI413530B (zh) | 2007-07-20 | 2013-11-01 | Kao Corp | 有機聚矽氧 |
| AU2008281281A1 (en) | 2007-07-31 | 2009-02-05 | University Of Saskatchewan | Genetic variation in Pro-Melanin-Concentrating Hormone gene affects carcass traits in cattle |
| US7812003B2 (en) | 2007-08-02 | 2010-10-12 | Safe Stephen H | Antisense microRNA and uses therefor |
| JP2010536787A (ja) | 2007-08-15 | 2010-12-02 | イデラ ファーマシューティカルズ インコーポレイテッド | Toll様受容体モジュレータ |
| CN101883777B (zh) | 2007-10-01 | 2015-03-25 | Isis制药公司 | 成纤维细胞生长因子受体4表达的反义调节 |
| KR100886139B1 (ko) | 2007-11-13 | 2009-02-27 | 주식회사 삼천리제약 | 올리고뉴클레오타이드의 제조방법 |
| AR069869A1 (es) | 2007-12-21 | 2010-02-24 | Exelixis Inc | Derivados de benzofuro[3,2-d]pirimidinas inhibidores de proteinquinasas,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer. |
| TWI340765B (en) | 2007-12-26 | 2011-04-21 | Ind Tech Res Inst | Oligonucleotide sequences and dna chip for identifying filamentous microorganisms and the identification method thereof |
| US20100309376A1 (en) | 2008-01-15 | 2010-12-09 | Yungchun Lei | Multimedia Presenting System, Multimedia Processing Apparatus Thereof, and Method for Presenting Video and Audio Signals |
| WO2009089659A1 (en) | 2008-01-18 | 2009-07-23 | Shanghai Targetdrug Co., Ltd. | Pyrollidine-based compounds |
| JP2011515653A (ja) | 2008-02-04 | 2011-05-19 | ガラパゴス・ナムローゼ・フェンノートシャップ | 神経変性疾患の治療に有用な標的配列及びそれらの同定方法 |
| JP2009190983A (ja) | 2008-02-12 | 2009-08-27 | Tokyo Institute Of Technology | オリゴヌクレオチド誘導体 |
| US8426378B2 (en) | 2008-03-21 | 2013-04-23 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising tricyclic nucelosides and methods for their use |
| WO2009120878A2 (en) | 2008-03-26 | 2009-10-01 | Alnylam Pharmaceuticals, Inc. | Non-natural ribonucleotides, and methods of use thereof |
| KR101806314B1 (ko) | 2008-04-03 | 2017-12-07 | 스프링 뱅크 파마슈티칼스, 인크. | 바이러스 감염증을 치료하기 위한 조성물 및 방법 |
| US9290534B2 (en) | 2008-04-04 | 2016-03-22 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside |
| DE112009001327A5 (de) | 2008-04-04 | 2011-03-31 | Universität Hamburg | Verfahren zur stereoselektiven Synthese von Phosphor-Verbindungen |
| US8679750B2 (en) | 2008-05-09 | 2014-03-25 | The University Of British Columbia | Methods and compositions for the treatment of Huntington'S disease |
| AU2009244013B2 (en) | 2008-05-09 | 2015-06-25 | The University Of British Columbia | Methods and compositions for the treatment of Huntington's disease |
| US8541387B2 (en) | 2008-05-22 | 2013-09-24 | Isis Pharmaceuticals, Inc. | Modulation of SMRT expression |
| US8541388B2 (en) | 2008-05-22 | 2013-09-24 | Isis Pharmaceuticals, Inc. | Methods for modulating expression of RBP4 |
| WO2009143391A2 (en) | 2008-05-22 | 2009-11-26 | Isis Pharmaceuticals, Inc | Methods for modulation expression of creb |
| WO2009148605A2 (en) | 2008-06-04 | 2009-12-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| CA2728559A1 (en) | 2008-07-03 | 2010-01-07 | Exelixis Inc. | Cdk modulators |
| WO2010030849A1 (en) | 2008-09-12 | 2010-03-18 | University Of Louisville Research Foundation, Inc. | Compositions and methods for treating cancer,inhibiting proliferation, and inducing cell death |
| US8163707B2 (en) | 2008-09-15 | 2012-04-24 | Enanta Pharmaceuticals, Inc. | 4′-allene-substituted nucleoside derivatives |
| WO2010039543A2 (en) | 2008-09-23 | 2010-04-08 | Traversa Therapeutics, Inc. | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference |
| WO2010036698A1 (en) | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
| WO2010036696A1 (en) | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Cyclohexenyl nucleic acid analogs |
| JP2012504962A (ja) | 2008-10-07 | 2012-03-01 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | テロメラーゼ阻害剤およびその使用方法 |
| ES2563984T3 (es) | 2008-10-22 | 2016-03-17 | Quark Pharmaceuticals, Inc. | Métodos para el tratamiento de trastornos oculares |
| EP2447274B1 (en) | 2008-10-24 | 2017-10-04 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
| EP2358397B1 (en) | 2008-10-24 | 2020-01-01 | Ionis Pharmaceuticals, Inc. | 5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom |
| BRPI0923225A2 (pt) | 2008-12-02 | 2016-10-04 | Chiralgen Ltd | metodo para sintese de acidos nucleicos modificados no atomo de fosforo |
| CN102307889A (zh) | 2008-12-23 | 2012-01-04 | 集润德斯股份公司 | 硫化剂及其用于寡核苷酸合成的用途 |
| WO2010080953A1 (en) | 2009-01-08 | 2010-07-15 | Isis Pharmaceuticals, Inc. | Transgenic murine model of human lipoprotein metabolism, hypercholesterolemia and cardiovascular disease |
| KR20100087540A (ko) | 2009-01-28 | 2010-08-05 | 삼성전자주식회사 | 잉크젯 기록용 잉크 조성물 |
| US20120264806A1 (en) | 2009-02-06 | 2012-10-18 | Bennett C Frank | Oligomeric compounds and excipients |
| EP2396409A2 (en) | 2009-02-10 | 2011-12-21 | Idera Pharmaceuticals, Inc. | Synthetic rna-based agonists of tlr7 |
| JP5766617B2 (ja) | 2009-02-20 | 2015-08-19 | ユニバーシティ・オブ・カンザス | 修飾された糖部分を有するノボビオシン類似体 |
| US8975389B2 (en) | 2009-03-02 | 2015-03-10 | Alnylam Pharmaceuticals, Inc. | Nucleic acid chemical modifications |
| EP2408796B1 (en) | 2009-03-16 | 2020-04-22 | Ionis Pharmaceuticals, Inc. | Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III |
| JP5685526B2 (ja) | 2009-03-31 | 2015-03-18 | 武田薬品工業株式会社 | ヌクレオシドの製造方法 |
| US8987222B2 (en) | 2009-04-08 | 2015-03-24 | University Of Massachusetts | Single nucleotide polymorphism (SNP) targeting therapies for the treatment of huntington'S disease |
| CA2759098A1 (en) | 2009-04-14 | 2010-10-21 | Smith Holdings, Llc | Methods and compositions for the treatment of medical conditions involving cellular programming |
| US9260493B2 (en) | 2009-05-07 | 2016-02-16 | The Regents Of The University Of California | Transducible delivery of nucleic acids using modified dsRNA binding domains |
| US20120142763A1 (en) | 2009-06-01 | 2012-06-07 | The Regents Of The University Of California | Nucleic acid delivery compositions and methods of use thereof |
| CA2764374C (en) | 2009-06-05 | 2019-11-19 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
| KR20220084437A (ko) | 2009-06-17 | 2022-06-21 | 바이오젠 엠에이 인코포레이티드 | 대상에게서 smn2 스플라이싱을 조정하기 위한 조성물 및 방법 |
| JP5670097B2 (ja) | 2009-06-19 | 2015-02-18 | 花王株式会社 | 二層分離型毛髪化粧料 |
| WO2010150789A1 (ja) | 2009-06-23 | 2010-12-29 | 武田薬品工業株式会社 | 核酸の合成法 |
| US8329024B2 (en) | 2009-07-06 | 2012-12-11 | Ada Technologies, Inc. | Electrochemical device and method for long-term measurement of hypohalites |
| EP2451461A4 (en) | 2009-07-06 | 2013-05-29 | Ontorii Inc | NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF |
| US8927513B2 (en) | 2009-07-07 | 2015-01-06 | Alnylam Pharmaceuticals, Inc. | 5′ phosphate mimics |
| EP2451974A2 (en) | 2009-07-08 | 2012-05-16 | Idera Pharmaceuticals, Inc. | Oligonucleotide-based compounds as inhibitors of toll-like receptors |
| WO2011010706A1 (ja) | 2009-07-23 | 2011-01-27 | 武田薬品工業株式会社 | Fgf21シスエレメント結合物質 |
| WO2011015572A1 (en) | 2009-08-03 | 2011-02-10 | Galapagos Nv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases |
| WO2011015573A1 (en) | 2009-08-03 | 2011-02-10 | Galapagos Nv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases |
| UA107360C2 (en) | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
| EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| US8927553B2 (en) | 2009-08-10 | 2015-01-06 | Daljit Singh Dhanoa | Deuterium-enriched alkyl sulfonamides and uses thereof |
| EP3626823A1 (en) | 2009-09-11 | 2020-03-25 | Ionis Pharmaceuticals, Inc. | Modulation of huntingtin expression |
| EP2479182B8 (en) | 2009-09-16 | 2016-07-13 | Wave Life Sciences Japan, Inc. | Novel protecting group for synthesizing rna and derivative thereof |
| WO2011038288A1 (en) | 2009-09-25 | 2011-03-31 | Isis Pharmaceuticals, Inc. | Modulation of ttc39 expression to increase hdl |
| AU2010308028A1 (en) | 2009-10-15 | 2012-04-19 | Pfizer Inc. | Pyrrolo[2,3-d] pyrimidine compounds |
| TWI475051B (zh) | 2009-11-18 | 2015-03-01 | 花王股份有限公司 | Organic polysiloxane |
| JP5809408B2 (ja) | 2009-11-25 | 2015-11-10 | 花王株式会社 | 毛髪化粧料 |
| EP2512246B1 (en) | 2009-12-17 | 2015-09-30 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
| US8647742B2 (en) | 2009-12-28 | 2014-02-11 | Achira Labs Pvt. Ltd. | Diagnostic gel composition, method for making a diagnostic gel composition |
| WO2011085271A2 (en) | 2010-01-08 | 2011-07-14 | Isis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
| US8750507B2 (en) | 2010-01-25 | 2014-06-10 | Cisco Technology, Inc. | Dynamic group creation for managed key servers |
| JP6018506B2 (ja) | 2010-02-08 | 2016-11-02 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | 対立遺伝子多様体の選択的低減 |
| ES2733708T3 (es) | 2010-02-08 | 2019-12-02 | Ionis Pharmaceuticals Inc | Reducción selectiva de variantes alélicas |
| RS53745B1 (sr) | 2010-02-10 | 2015-06-30 | Glaxosmithkline Llc | 6-amino-2-{[(1s)-1-metilbutil]oksi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8h-purin-8-on-maleat |
| WO2011108682A1 (ja) | 2010-03-05 | 2011-09-09 | 国立大学法人 東京大学 | リボヌクレオシドホスホロチオエートの製造方法 |
| WO2011127175A1 (en) | 2010-04-06 | 2011-10-13 | Isis Pharmaceuticals, Inc. | Modulation of cd130 (gp130) expression |
| CN102844434A (zh) | 2010-04-07 | 2012-12-26 | Isis制药公司 | Cetp表达的调节 |
| US9725479B2 (en) | 2010-04-22 | 2017-08-08 | Ionis Pharmaceuticals, Inc. | 5′-end derivatives |
| WO2011139699A2 (en) | 2010-04-28 | 2011-11-10 | Isis Pharmaceuticals, Inc. | 5' modified nucleosides and oligomeric compounds prepared therefrom |
| WO2011139702A2 (en) | 2010-04-28 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Modified nucleosides and oligomeric compounds prepared therefrom |
| WO2011139911A2 (en) | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
| EP2563921B1 (en) | 2010-04-30 | 2016-11-23 | Cellectis | Method for modulating double-strand break-induced homologous recombination |
| GB201008902D0 (en) | 2010-05-27 | 2010-07-14 | Imp Innovations Ltd | Membrane enhanced polymer sythesis |
| US20130253168A1 (en) | 2010-08-31 | 2013-09-26 | Steven L. Colletti | Novel single chemical entities and methods for delivery of oligonucleotides |
| DK2620428T3 (da) | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
| EP2623600A4 (en) | 2010-09-30 | 2014-11-26 | Lsip Llc | EXPRESSION INHIBITOR OF A DOMINANTLY MUTANT GENE |
| KR101381048B1 (ko) | 2010-10-20 | 2014-04-14 | 씨제이제일제당 (주) | O-포스포세린 생산 균주 및 이로부터 생산된 o-포스포세린으로부터 l-시스테인 또는 이의 유도체의 생산방법 |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| EP3702460A1 (en) | 2010-11-12 | 2020-09-02 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| EP2647644B1 (en) | 2010-11-30 | 2020-09-09 | Wave Life Sciences Japan, Inc. | 2'-o-modified rna |
| US20140050778A1 (en) | 2010-12-28 | 2014-02-20 | University Of Rochester | Nucleic acid binding compounds, methods of making, and use thereof |
| US10017764B2 (en) | 2011-02-08 | 2018-07-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| ES2739804T3 (es) | 2011-02-12 | 2020-02-04 | Univ Iowa Res Found | Compuestos terapéuticos |
| WO2012151324A1 (en) | 2011-05-02 | 2012-11-08 | Isis Pharmaceuticals, Inc. | Antisense compounds targeting genes associated with usher syndrome |
| FR2975600B1 (fr) | 2011-05-24 | 2013-07-05 | Assist Publ Hopitaux De Paris | Agents pour le traitement de tumeurs |
| CN107365339A (zh) | 2011-07-19 | 2017-11-21 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| RU2014106024A (ru) | 2011-07-19 | 2015-08-27 | Юниверсити Оф Айдахо | Варианты осуществления зонда и способы направленного действия на нуклеиновые кислоты |
| US20140303235A1 (en) | 2011-08-11 | 2014-10-09 | Isis Pharmaceuticals, Inc. | Linkage modified gapped oligomeric compounds and uses thereof |
| US9282242B2 (en) | 2011-08-24 | 2016-03-08 | Htc Corporation | Method and electric device for taking panoramic photograph |
| EP2751269B1 (en) | 2011-08-29 | 2016-03-23 | Ionis Pharmaceuticals, Inc. | Methods and compounds useful in conditions related to repeat expansion |
| US20140080896A1 (en) | 2011-08-30 | 2014-03-20 | The Regents Of The University Of California | Identification of small molecules that facilitate therapeutic exon skipping |
| WO2013030588A1 (en) | 2011-08-31 | 2013-03-07 | The University Of Manchester | Method for diagnosing a neurodegenerative disease |
| US20140255936A1 (en) | 2011-09-09 | 2014-09-11 | Mayo Foundation For Medical Education And Research | Detecting frontotemporal dementia and amyotrophic lateral sclerosis |
| WO2013082548A1 (en) | 2011-11-30 | 2013-06-06 | Sarepta Therapeutics, Inc. | Oligonucleotides for treating expanded repeat diseases |
| JP2015502365A (ja) | 2011-12-12 | 2015-01-22 | オンコイミューニン,インコーポレイティド | オリゴヌクレオチドのイン−ビボ送達 |
| CN102675386B (zh) | 2011-12-24 | 2014-07-02 | 河南科技大学 | 一种龙胆苦苷分离提纯方法 |
| US8957042B2 (en) | 2012-03-07 | 2015-02-17 | The Texas A&M University System | Cancer treatment targeting non-coding RNA overexpression |
| NZ629996A (en) | 2012-03-13 | 2016-10-28 | Gilead Sciences Inc | 2’- substituted carba-nucleoside analogs for antiviral treatment |
| US9809616B2 (en) | 2012-10-29 | 2017-11-07 | Emory University | Pyrimidine nucleosides and their monophosphate prodrugs for the treatment of viral infections and cancer |
| KR20130114435A (ko) | 2012-04-09 | 2013-10-17 | 삼성전자주식회사 | 다수의 전극을 갖는 생분자 검출 장치 |
| PT2841578T (pt) | 2012-04-23 | 2017-08-10 | Biomarin Tech Bv | Resumo |
| MD20140134A2 (ro) | 2012-05-22 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice |
| WO2013179412A1 (ja) | 2012-05-30 | 2013-12-05 | 北海道システム・サイエンス株式会社 | 高分散性液相支持体を用いたオリゴヌクレオチド合成法 |
| DK2872147T3 (da) | 2012-07-13 | 2023-02-20 | Wave Life Sciences Ltd | Fremgangsmåde til fremstilling af kirale oligonukleotider |
| WO2014010250A1 (en) | 2012-07-13 | 2014-01-16 | Chiralgen, Ltd. | Asymmetric auxiliary group |
| SG11201500243WA (en) | 2012-07-13 | 2015-04-29 | Shin Nippon Biomedical Lab Ltd | Chiral nucleic acid adjuvant |
| EP4253395A3 (en) | 2012-08-06 | 2023-11-29 | Alnylam Pharmaceuticals, Inc. | Processes for the preparation of carbohydrate conjugated rna agents |
| WO2014028739A1 (en) | 2012-08-15 | 2014-02-20 | Isis Pharmaceuticals, Inc. | Method of preparing oligomeric compounds using modified capping protocols |
| EP4086347A3 (en) | 2012-10-12 | 2023-01-11 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| EP2906697A4 (en) | 2012-10-15 | 2016-06-22 | Ionis Pharmaceuticals Inc | METHOD FOR MONITORING THE C9ORF72 EXPRESSION |
| US10443052B2 (en) | 2012-10-15 | 2019-10-15 | Ionis Pharmaceuticals, Inc. | Compositions for modulating C9ORF72 expression |
| FI2906696T4 (fi) | 2012-10-15 | 2023-03-18 | Menetelmiä c9orf72:n ilmentymisen moduloimiseksi | |
| EP2725029A1 (en) | 2012-10-29 | 2014-04-30 | Laboratoire Biodim | New antibacterial compounds and biological applications thereof |
| EP2915815B1 (en) | 2012-10-31 | 2018-01-17 | Takeda Pharmaceutical Company Limited | New modified nucleic acid |
| CA2889044A1 (en) | 2012-11-15 | 2014-05-22 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| BR112015012051A2 (pt) | 2012-11-26 | 2017-12-12 | Roche Innovation Ct Copenhagen As | composições e métodos para modulação de expressão de fgfr3 |
| US9211300B2 (en) | 2012-12-19 | 2015-12-15 | Idenix Pharmaceuticals Llc | 4′-fluoro nucleosides for the treatment of HCV |
| CA2893801A1 (en) | 2013-01-30 | 2014-08-07 | F. Hoffmann-La Roche Ag | Lna oligonucleotide carbohydrate conjugates |
| WO2014118272A1 (en) | 2013-01-30 | 2014-08-07 | Santaris Pharma A/S | Antimir-122 oligonucleotide carbohydrate conjugates |
| EP2951304B1 (en) | 2013-02-04 | 2020-07-08 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| EP2958998B1 (en) | 2013-02-22 | 2017-12-27 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) molecules containing a 2' internucleoside linkage |
| WO2014154486A1 (en) | 2013-03-28 | 2014-10-02 | Syngenta Participations Ag | Methods of controlling neonicotinoid resistant pests |
| CN105072911A (zh) | 2013-03-28 | 2015-11-18 | 先正达参股股份有限公司 | 控制新烟碱抗性有害生物的方法 |
| PL2992098T3 (pl) | 2013-05-01 | 2019-09-30 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji hbv i ttr |
| JP6477464B2 (ja) | 2013-05-24 | 2019-03-06 | 味の素株式会社 | モルフォリノオリゴヌクレオチドの製造方法 |
| US20160130582A1 (en) | 2013-05-24 | 2016-05-12 | Roche Innovation Center Copenhagen A/S | Oligonucleotide modulators of b-cell cll/lymphoma 11a (bcl11a) and uses thereof |
| WO2014205451A2 (en) | 2013-06-21 | 2014-12-24 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| MX367083B (es) | 2013-06-27 | 2019-08-05 | Roche Innovation Ct Copenhagen As | Oligomeros antisentido y conjugados con diana en la proteina-convertasa subtilisina/kexina tipo 9(pcsk9). |
| TWI702046B (zh) | 2013-07-19 | 2020-08-21 | 美商Ionis製藥公司 | 用於調節τ蛋白表現之組合物 |
| CA2919268C (en) | 2013-07-25 | 2023-09-05 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
| EP3027617B1 (en) | 2013-07-31 | 2026-02-18 | Ionis Pharmaceuticals, Inc. | Methods and compounds useful in conditions related to repeat expansion |
| BR112016004352A2 (pt) | 2013-09-06 | 2017-09-12 | Syngenta Participations Ag | compostos inseticidas |
| EP3052511A4 (en) | 2013-10-02 | 2017-05-31 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| WO2015051366A2 (en) | 2013-10-04 | 2015-04-09 | Novartis Ag | Novel formats for organic compounds for use in rna interference |
| MY192689A (en) | 2013-10-11 | 2022-09-01 | Ionis Pharmaceuticals Inc | Compositions for modulating c9orf72 expression |
| WO2015057727A1 (en) | 2013-10-14 | 2015-04-23 | Isis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
| AU2014337506B2 (en) | 2013-10-14 | 2020-10-15 | Ionis Pharmaceuticals, Inc. | Methods for modulating expression of C9ORF72 antisense transcript |
| MX391904B (es) | 2013-11-11 | 2025-03-12 | Sangamo Biosciences Inc | Un represor genetico para usarse en el tratamiento de la enfermedad de huntington. |
| KR20160083876A (ko) | 2013-11-14 | 2016-07-12 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | ApoB 안티센스 접합체 화합물 |
| US20150167017A1 (en) | 2013-12-13 | 2015-06-18 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
| EP3095461A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
| EP3095459A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
| WO2015108046A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
| EP3094728B1 (en) | 2014-01-16 | 2022-03-09 | Wave Life Sciences Ltd. | Chiral design |
| JP6756700B2 (ja) | 2014-03-18 | 2020-09-16 | ユニバーシティ オブ マサチューセッツ | 筋萎縮性側索硬化症を処置するためのrAAVベースの組成物および方法 |
| US9926556B2 (en) | 2014-04-28 | 2018-03-27 | Ionis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds |
| WO2015168589A2 (en) | 2014-05-01 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating angiopoietin-like 3 expression |
| BR112016025849A2 (pt) | 2014-05-08 | 2017-10-17 | Chdi Foundation Inc | métodos e composições para o tratamento da doença de huntington |
| AU2015264263B2 (en) | 2014-05-20 | 2021-08-05 | University Of Iowa Research Foundation | Huntington's disease therapeutic compounds |
| US20160017327A1 (en) | 2014-07-11 | 2016-01-21 | The Johns Hopkins University | Phosphorodiamidate morpholino oligomers (pmos) and their use in suppression of mutant huntingtin expression and attenuation of neurotoxicity |
| WO2016011226A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| EP2982758A1 (en) | 2014-08-04 | 2016-02-10 | Centre Hospitalier Universitaire Vaudois (CHUV) | Genome editing for the treatment of huntington's disease |
| PL3178807T3 (pl) | 2014-08-07 | 2020-08-24 | Takeda Pharmaceutical Company Limited | Lipid kationowy |
| WO2016024205A1 (en) | 2014-08-15 | 2016-02-18 | Pfizer Inc. | Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene |
| WO2016037191A1 (en) | 2014-09-05 | 2016-03-10 | Health Research, Inc. | Use of huntingtin-derived plasmids and peptides for active immunization as a huntington's disease (hd) therapeutic |
| EP3221329A1 (en) | 2014-11-19 | 2017-09-27 | Roche Innovation Center Copenhagen A/S | Lna gapmer oligonucleotides comprising chiral phosphorothioate linkages |
| DK3234131T3 (da) | 2014-12-16 | 2020-06-29 | Roche Innovation Ct Copenhagen As | Fremgangsmåde til screening af kiral toksicitet |
| AU2015370903B2 (en) | 2014-12-24 | 2021-06-17 | Uniqure Ip B.V. | RNAi induced huntingtin gene suppression |
| US9688707B2 (en) | 2014-12-30 | 2017-06-27 | Ionis Pharmaceuticals, Inc. | Bicyclic morpholino compounds and oligomeric compounds prepared therefrom |
| US10793855B2 (en) | 2015-01-06 | 2020-10-06 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of C9ORF72 antisense transcript |
| US20180023081A1 (en) | 2015-02-04 | 2018-01-25 | Bristol-Myers Squibb Company | Lna oligonucleotides with alternating flanks |
| ES2893114T3 (es) | 2015-02-04 | 2022-02-08 | Bristol Myers Squibb Co | Métodos para seleccionar moléculas terapéuticas |
| CA3255657A1 (en) | 2015-02-10 | 2025-12-01 | Genzyme Corporation | VARIANT RNAi |
| JP2018510621A (ja) | 2015-02-13 | 2018-04-19 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | パタチン様ホスホリパーゼドメイン含有3(PNPLA3)iRNA組成物およびその使用方法 |
| EP3262174A4 (en) | 2015-02-23 | 2018-10-17 | Ionis Pharmaceuticals, Inc. | Compounds and methods for increasing antisense activity |
| EP3265098B1 (en) | 2015-03-03 | 2025-03-26 | Ionis Pharmaceuticals, Inc. | Compositions for modulating mecp2 expression |
| WO2016145142A1 (en) | 2015-03-10 | 2016-09-15 | Emory University | Nucleotide and nucleoside therapeutics compositions and uses related thereto |
| WO2016154096A1 (en) | 2015-03-20 | 2016-09-29 | Ionis Pharmaceuticals, Inc. | Modulation of smggds expression |
| RS60762B1 (sr) | 2015-04-03 | 2020-10-30 | Univ Massachusetts | Oligonukleotidna jedinjenja za ciljane irnk hantingtina |
| US10851371B2 (en) | 2015-04-10 | 2020-12-01 | Ionis Pharmaceuticals, Inc. | Modulation of SMN expression |
| WO2016168592A2 (en) | 2015-04-16 | 2016-10-20 | Ionis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
| WO2016167780A1 (en) | 2015-04-16 | 2016-10-20 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
| WO2016209862A1 (en) | 2015-06-23 | 2016-12-29 | Alnylam Pharmaceuticals, Inc. | Glucokinase (gck) irna compositions and methods of use thereof |
| JP2018519811A (ja) | 2015-06-29 | 2018-07-26 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | 修飾crispr rna及び修飾単一crispr rnaならびにその使用 |
| CA2991894A1 (en) | 2015-07-10 | 2017-01-19 | Ionis Pharmaceuticals, Inc. | Modulators of diacyglycerol acyltransferase 2 (dgat2) |
| US10494632B2 (en) | 2015-07-10 | 2019-12-03 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof |
| CA3205381A1 (en) | 2015-07-17 | 2017-01-26 | Alnylam Pharmaceuticals, Inc. | Multi-targeted single entity conjugates |
| CN117965536A (zh) | 2015-07-22 | 2024-05-03 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| WO2017019660A1 (en) | 2015-07-27 | 2017-02-02 | Alnylam Pharmaceuticals, Inc. | Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof |
| LT3329002T (lt) | 2015-07-31 | 2021-01-11 | Alnylam Pharmaceuticals, Inc. | Transtiretino (ttr) irnr kompozicijos ir jų naudojimo būdai, skirti naudoti su ttr susijusių ligų gydymui arba prevencijai |
| KR20180043819A (ko) | 2015-08-24 | 2018-04-30 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | Lna-g 방법 |
| EP3340994A1 (en) | 2015-08-25 | 2018-07-04 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder |
| US10889813B2 (en) | 2015-09-02 | 2021-01-12 | Alnylam Pharmaceuticals, Inc. | Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof |
| US10874686B2 (en) | 2015-10-01 | 2020-12-29 | Memorial Sloan-Kettering Cancer Center | Anthranilyl-adenosinemonosulfamate analogs and uses thereof |
| CA3000709A1 (en) | 2015-10-01 | 2017-04-06 | Memorial Sloan-Kettering Cancer Center | Inhibitors of menaquinone biosynthesis |
| WO2017055423A1 (en) | 2015-10-02 | 2017-04-06 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugation process |
| MA46427A (fr) | 2015-10-09 | 2018-08-15 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| EP3183347A4 (en) | 2015-10-17 | 2018-04-18 | Lifesplice Pharma LLC | Splice modulating oligonucleotides and methods of use thereof |
| WO2017068087A1 (en) | 2015-10-22 | 2017-04-27 | Roche Innovation Center Copenhagen A/S | Oligonucleotide detection method |
| WO2017067970A1 (en) | 2015-10-22 | 2017-04-27 | Roche Innovation Center Copenhagen A/S | In vitro toxicity screening assay |
| WO2017079291A1 (en) | 2015-11-02 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating c90rf72 |
| HK1258434A1 (zh) | 2015-11-12 | 2019-11-08 | F. Hoffmann-La Roche Ag | 来自灵长类物种的标准化神经元细胞测定试验 |
| MA43822A (fr) | 2016-03-13 | 2018-11-28 | Wave Life Sciences Ltd | Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides |
| CA3013683C (en) | 2016-03-14 | 2021-07-13 | F. Hoffmann-La Roche Ag | Oligonucleotides for reduction of pd-l1 expression |
| WO2017157672A1 (en) | 2016-03-18 | 2017-09-21 | Roche Innovation Center Copenhagen A/S | Acyl-protected l-lna-guanosine monomers |
| WO2017165489A1 (en) | 2016-03-23 | 2017-09-28 | Emory University | Antiviral agents for treating zika and dengue virus infections |
| WO2017180835A1 (en) | 2016-04-13 | 2017-10-19 | Ionis Pharmaceuticals, Inc. | Methods for reducing c9orf72 expression |
| WO2017178656A1 (en) | 2016-04-14 | 2017-10-19 | Roche Innovation Center Copenhagen A/S | TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE |
| EP3452596A4 (en) | 2016-05-04 | 2020-03-18 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS |
| JP2019516679A (ja) | 2016-05-04 | 2019-06-20 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | 生物活性剤に関する方法および組成物 |
| WO2017194498A1 (en) | 2016-05-12 | 2017-11-16 | Roche Innovation Center Copenhagen A/S | Enhanced coupling of stereodefined oxazaphospholidine phosphoramidite monomers to nucleoside or oligonucleotide |
| JP7083756B2 (ja) | 2016-05-13 | 2022-06-13 | エフ.ホフマン-ラ ロシュ アーゲー | タンパク質系試料回収マトリックス及び装置 |
| EP3458464B1 (en) | 2016-05-18 | 2026-04-15 | ETH Zurich | Stereoselective synthesis of phosphorothioate oligoribonucleotides |
| US11013757B2 (en) | 2016-06-03 | 2021-05-25 | Wave Life Sciences Ltd. | Oligonucleotides, compositions and methods thereof |
| DK3473270T5 (da) | 2016-06-20 | 2024-09-09 | Genahead Bio Inc | Konjugat af antistof-lægemiddel |
| US20190264267A1 (en) | 2016-07-25 | 2019-08-29 | Wave Life Sciences Ltd. | Phasing |
| WO2018098264A1 (en) | 2016-11-23 | 2018-05-31 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| CN111164091B (zh) | 2017-06-02 | 2025-01-07 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
| CA3065523A1 (en) | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| US11603532B2 (en) | 2017-06-02 | 2023-03-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| WO2018237194A1 (en) | 2017-06-21 | 2018-12-27 | Wave Life Sciences Ltd. | Compounds, compositions and methods for synthesis |
| AU2018316159A1 (en) | 2017-08-08 | 2020-02-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| CN111108096A (zh) | 2017-09-18 | 2020-05-05 | 波涛生命科学有限公司 | 寡核苷酸制备技术 |
| EP3694530A4 (en) | 2017-10-12 | 2021-06-30 | Wave Life Sciences Ltd. | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
| JP2021521140A (ja) | 2018-04-12 | 2021-08-26 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | オリゴヌクレオチド組成物及びその使用方法 |
| CA3098624A1 (en) | 2018-05-11 | 2019-11-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| AU2019392928A1 (en) | 2018-12-06 | 2021-06-17 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| EP3917497A4 (en) | 2019-02-01 | 2023-06-07 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF |
| AU2020241559A1 (en) | 2019-03-20 | 2021-11-11 | Wave Life Sciences Ltd. | Technologies useful for oligonucleotide preparation |
| JPWO2020196662A1 (cg-RX-API-DMAC7.html) | 2019-03-25 | 2020-10-01 | ||
| EP3958872A4 (en) | 2019-04-25 | 2024-07-03 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| MX2021012981A (es) | 2019-04-25 | 2022-01-18 | Wave Life Sciences Ltd | Composiciones de oligonucleotido y metodos de uso de las mismas. |
| EP3965780A4 (en) | 2019-05-09 | 2023-10-25 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE |
| CA3154768A1 (en) | 2019-10-06 | 2021-04-15 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| CA3156176A1 (en) | 2019-10-06 | 2021-04-15 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| AU2021230473A1 (en) | 2020-03-01 | 2022-09-22 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| AU2021277407A1 (en) | 2020-05-22 | 2022-11-17 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| MX2022014606A (es) | 2020-05-22 | 2023-03-08 | Wave Life Sciences Ltd | Composiciones de oligonucleótidos bicatenarios y métodos relacionados con las mismas. |
| CN115989041A (zh) | 2020-08-24 | 2023-04-18 | 波涛生命科学有限公司 | 经工程化为表达adar1的细胞和非人动物及其用途 |
| EP4200616A1 (en) | 2020-08-24 | 2023-06-28 | Wave Life Sciences Ltd. | Immunoassays for detecting wild type huntingtin protein and methods of treatment employing such immunoassays |
| US20230416847A1 (en) | 2020-09-24 | 2023-12-28 | Mayo Foundation For Medical Education And Research | Screening platforms |
| JP2023548584A (ja) | 2020-11-08 | 2023-11-17 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド組成物及びその方法 |
| CN116507724A (zh) | 2020-11-08 | 2023-07-28 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| CA3232070A1 (en) | 2021-09-26 | 2023-03-30 | Prashant MONIAN | Oligonucleotide compositions and methods thereof |
| EP4404942A4 (en) | 2021-09-26 | 2026-06-17 | Wave Life Sciences Ltd | Compositions for the Editing of Transcripts MECP2 and Related Processes |
| AU2021471586A1 (en) | 2021-10-27 | 2024-05-09 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| EP4422645A4 (en) | 2021-10-27 | 2025-12-03 | Wave Life Sciences Ltd | OLIGONUCLEOTID COMPOSITIONS AND THEIR METHODS OF USE |
| EP4476202A4 (en) | 2022-02-11 | 2026-06-10 | Wave Life Sciences Ltd | STEREOSELECTIVE TECHNOLOGIES FOR CHIRICAL COMPOUNDS |
| US20250197857A1 (en) | 2022-03-02 | 2025-06-19 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof for exon skipping |
| EP4507700A2 (en) | 2022-04-15 | 2025-02-19 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods relating thereto |
| CN119452084A (zh) | 2022-05-12 | 2025-02-14 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| EP4569115A4 (en) | 2022-08-11 | 2026-07-15 | Wave Life Sciences Ltd | OLIGONUCLEOTID COMPOSITIONS AND ASSOCIATED PROCESSES |
-
2015
- 2015-01-16 EP EP15719826.8A patent/EP3094728B1/en active Active
- 2015-01-16 BR BR112016016400A patent/BR112016016400A2/pt not_active Application Discontinuation
- 2015-01-16 DK DK15719826.8T patent/DK3094728T3/da active
- 2015-01-16 KR KR1020227024673A patent/KR20220106232A/ko not_active Abandoned
- 2015-01-16 AU AU2015207773A patent/AU2015207773B2/en active Active
- 2015-01-16 US US15/112,146 patent/US10160969B2/en active Active
- 2015-01-16 WO PCT/IB2015/000395 patent/WO2015107425A2/en not_active Ceased
- 2015-01-16 SG SG10201912897UA patent/SG10201912897UA/en unknown
- 2015-01-16 KR KR1020167022289A patent/KR102423317B1/ko active Active
- 2015-01-16 KR KR1020247037406A patent/KR20240164968A/ko not_active Ceased
- 2015-01-16 ES ES15719826T patent/ES2917473T3/es active Active
- 2015-01-16 SG SG11201605782UA patent/SG11201605782UA/en unknown
- 2015-01-16 CN CN202110675033.6A patent/CN113278617A/zh active Pending
- 2015-01-16 CN CN201580011393.9A patent/CN106068325B/zh active Active
- 2015-01-16 PL PL15719826T patent/PL3094728T3/pl unknown
- 2015-01-16 MX MX2016009290A patent/MX2016009290A/es unknown
- 2015-01-16 MY MYPI2016001319A patent/MY193116A/en unknown
- 2015-01-16 KR KR1020257039389A patent/KR20250172722A/ko active Pending
- 2015-01-16 RU RU2016133035A patent/RU2016133035A/ru not_active Application Discontinuation
- 2015-01-16 CA CA2936712A patent/CA2936712A1/en active Pending
- 2015-01-16 KR KR1020237036550A patent/KR20230152178A/ko not_active Ceased
- 2015-01-16 EP EP22160683.3A patent/EP4137572A1/en active Pending
- 2015-01-16 PT PT157198268T patent/PT3094728T/pt unknown
- 2015-01-16 JP JP2016564442A patent/JP6382344B2/ja active Active
-
2016
- 2016-07-11 IL IL246703A patent/IL246703A0/en unknown
- 2016-07-15 CL CL2016001814A patent/CL2016001814A1/es unknown
-
2018
- 2018-08-01 JP JP2018145256A patent/JP6757373B2/ja active Active
- 2018-08-22 US US16/109,638 patent/US10815482B2/en active Active
-
2020
- 2020-08-28 JP JP2020144129A patent/JP7224319B2/ja active Active
- 2020-09-09 US US17/016,313 patent/US12180472B2/en active Active
-
2021
- 2021-09-16 AU AU2021232770A patent/AU2021232770A1/en not_active Abandoned
-
2023
- 2023-02-07 JP JP2023016863A patent/JP7662687B2/ja active Active
-
2024
- 2024-05-14 AU AU2024203173A patent/AU2024203173A1/en active Pending
- 2024-11-19 US US18/953,020 patent/US20250313836A1/en active Pending
-
2025
- 2025-04-03 JP JP2025061939A patent/JP2025106395A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7662687B2 (ja) | キラルデザイン | |
| KR102450907B1 (ko) | 키랄 제어 | |
| CN108137492B (zh) | 寡核苷酸组合物及其方法 | |
| EP4344744A2 (en) | Oligonucleotide compositions and methods thereof | |
| JP2019516680A (ja) | オリゴヌクレオチド組成物およびその方法 | |
| HK40088424A (en) | Chiral design | |
| HK40057539A (en) | Chiral design | |
| HK40042428A (en) | Chiral control | |
| HK1230658B (en) | Chiral design |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A16-div-PA0104 St.27 status event code: A-0-1-A10-A18-div-PA0104 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A16-div-PA0104 St.27 status event code: A-0-1-A10-A18-div-PA0104 |
|
| PC1904 | Unpaid initial registration fee |
St.27 status event code: N-2-6-B10-B12-nap-PC1904 St.27 status event code: A-2-2-U10-U14-oth-PC1904 |